albendazole has been researched along with Bancroftian Elephantiasis in 266 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 7.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| "No other short-course oral treatment for onchocerciasis has been demonstrated to have macrofilaricidal activity." | 7.30 | A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis. ( Doe, F; Dubben, B; Fetcho, N; Fischer, K; Fischer, PU; Gordor, S; Goss, CW; Gyasi, ME; Hoerauf, A; Hong, AR; Kanza, E; King, CL; Laryea, R; Lew, D; Opoku, NO; Seidu, MA; Weil, GJ, 2023) |
| "We assessed the impact of three annual vs five semiannual rounds of mass drug administration (MDA) with ivermectin plus albendazole followed by praziquantel for the control or elimination of lymphatic filariasis (LF), onchocerciasis, soil-transmitted helminth (STH) infections and schistosomiasis in Lofa County, Liberia." | 5.51 | Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia. ( Bolay, FK; Curtis, K; Eneanya, OA; Fischer, K; Fischer, PU; Gankpala, L; Goss, CW; Gray, EB; Momolu, AT; Nyan, ES; Weil, GJ, 2022) |
| "The prevalence of lymphatic filariasis in adults above 18 years was 42." | 5.43 | Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. ( Clowes, P; Haule, A; Hoelscher, M; Hoerauf, A; Kowuor, D; Kroidl, I; Löscher, T; Maboko, L; Mabuye, J; Maganga, L; Makunde, WH; Malecela, MN; Mgeni, N; Mviombo, P; Mwingira, U; Pitter, B; Saathof, E, 2016) |
| "punctulatus vector." | 5.35 | The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. ( Bockarie, MJ; Kastens, W; Kazura, JW; King, CL; Laney, SJ; Susapu, M; Weil, GJ; Williams, SA, 2008) |
| " This study reports on the safety of a combination of albendazole, ivermectin and praziquantel in the treatment of lymphatic filariasis (LF), schistosomiasis and soil-transmitted helminthiasis (STH) in infected children." | 5.15 | A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. ( Kabatereine, N; Namwanje, H; Olsen, A, 2011) |
| "Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several rounds of treatment with one or two drugs have been implemented in the past." | 5.13 | Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study. ( Biswas, G; Bradley, MH; Chitsulo, L; Engels, D; Gabrielli, AF; Haji, HJ; Mohammed, KA; Molyneux, DH; Mubila, L; Savioli, L, 2008) |
| "Our findings strongly support WHO's provisional strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered." | 3.85 | Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. ( Boussinesq, M; Chesnais, CB; Fischer, PU; Missamou, F; Pion, SDS; Weil, GJ, 2017) |
| "Ivermectin and albendazole are used in annual mass drug administration (MDA) for the lymphatic filariasis elimination programmes in African countries co-endemic for onchocerciasis, but have additional impact on soil transmitted helminths and the ectoparasitic mite which causes scabies." | 3.78 | Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis--a rapid assessment methodology to assess impact. ( Deb, RM; Mohammed, KA; Molyneux, DH; Stanton, MC, 2012) |
| "Two-arm comparative study in northern Ghana integrated praziquantel distribution into an existing lymphatic filariasis and onchocerciasis control programme using Community Directed Distributors." | 3.77 | Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis. ( Aborigo, R; Adjuik, M; Akweongo, P; Amankwa, J; Anto, F; Anyorigiya, T; Asoala, V; Bimi, L; Hodgson, A; Oduro, A, 2011) |
| " Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons." | 3.77 | Costs of integrated mass drug administration for neglected tropical diseases in Haiti. ( Baker, M; Brady, MA; Desir, L; Direny, A; Goldman, AS; Linehan, M; Oscard, R; Vely, JF, 2011) |
| "No other short-course oral treatment for onchocerciasis has been demonstrated to have macrofilaricidal activity." | 3.30 | A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis. ( Doe, F; Dubben, B; Fetcho, N; Fischer, K; Fischer, PU; Gordor, S; Goss, CW; Gyasi, ME; Hoerauf, A; Hong, AR; Kanza, E; King, CL; Laryea, R; Lew, D; Opoku, NO; Seidu, MA; Weil, GJ, 2023) |
| "One hundred sixty-four individuals were treated, and monitored for treatment emergent adverse events (TEAE)." | 3.30 | Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study. ( Bjerum, CM; Budge, PJ; Fischer, PU; Gabo, PT; Goss, CW; King, CL; Koudou, BG; Lew, D; Ouattara, AF; Weil, GJ, 2023) |
| " Adverse events (AE) were assessed by active follow-up for 2 days and passive follow-up for an additional 5 days." | 3.11 | Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial. ( Amuga, M; Bieb, S; Bjerum, C; Goss, CW; Howard, C; John, LN; Karl, S; Kerry, Z; King, CL; Kotty, B; Kualawi, M; Kumai, S; Laman, M; Lorry, L; Makita, L; O'Brian, K; Pomat, W; Robinson, LJ; Samuel, A; Tavul, L; Tisch, DJ; Wangi, J; Weil, GJ, 2022) |
| "Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease." | 3.01 | An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. ( Alfian, R; Bogus, J; Christian, M; Destani, Y; Djuardi, Y; Fischer, PU; Iskandar, E; Lew, D; Lomiga, A; Maylasari, R; Minggu, D; Supali, T; Weil, GJ, 2021) |
| " A field study in Mali suggested the rates of adverse events were similar with combined or separate administration, but was underpowered." | 3.01 | Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review. ( Gebre, T; Mabey, DCW; Marks, M; McPherson, S; Seife, F; Solomon, AW; Solomon, H, 2023) |
| " Adverse events (AEs) were monitored actively for two days and passively for five more days." | 3.01 | An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. ( Dwivedi, GP; Jambulingam, P; Krishnamoorthy, K; Kuttiatt, VS; Rahi, M; Raju, HKK; Somani, RK; Srividya, A; Subramanian, S; Suryaprakash, MK; Weil, GJ, 2021) |
| " Participants were monitored for adverse events (AE), parasite antigenemia, and microfilaremia." | 2.94 | Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. ( Beau de Rochars, VM; Bogus, J; Direny, AN; Dubray, CL; Ernest, JR; Fayette, CR; Goss, CW; Hast, M; Lemoine, JF; O'Brian, K; Pavilus, GE; Sabin, DF; Sircar, AD; Weil, GJ; Wiegand, RE, 2020) |
| " Both treatments were well tolerated, and there were no serious adverse events." | 2.94 | Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial. ( Aboulaye, M; Andersen, BJ; Bjerum, CM; King, CL; Kouadio, O; Koudou, BG; Marius, VK; Ouattara, AF; Weil, GJ, 2020) |
| "Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration using the well-established and safe combination of diethylcarbamazine and albendazole (DA) since 2002." | 2.94 | The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. ( Grobler, AC; Hardy, M; Kaldor, JM; Kama, M; King, CL; Robinson, LJ; Romani, L; Samuela, J; Steer, AC; Tuicakau, M; Weil, GJ; Whitfeld, MJ, 2020) |
| " Adverse events (AEs) are common after LF treatment." | 2.90 | Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. ( Andersen, BJ; Curtis, K; Fischer, PU; Hertz, MI; King, CL; Kupritz, J; Meite, A; Mitreva, M; Rosa, BA; Serge, T; Weil, GJ, 2019) |
| "In this open-label cohort study, treatment-naïve microfilaremic (>50 mf/mL, n = 32) and uninfected (circulating filarial antigen negative, n = 24) adults residing in Agboville district, Côte d'Ivoire, were treated with a single dose of IVM plus DEC plus ALB, and evaluated for adverse events (AEs) until 7 days post treatment." | 2.90 | Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. ( Bjerum, CM; Chhonker, YS; Edi, C; King, CL; Koudou, BG; Méité, A; Murry, DJ; Ouattara, AF; Penali, LK; Weil, GJ, 2019) |
| " This was independent of age (p = 0·27), symptomatic status (p = 0·57) and semi-annual/bi-annual dosing (p = 0·46)." | 2.84 | Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment. ( Agrawala, BK; Das, BK; Dwibedi, B; Horton, J; Kar, SK; Ramachandran, CP, 2017) |
| " The triple therapy had a similar adverse effect compared with the dual therapy group." | 2.82 | Efficacy and safety of triple therapy versus dual therapy for lymphatic filariasis: A systematic review and meta-analysis. ( Abd-Elsalam, S; Abdelazeem, B; Abuelazm, MT; Ashraf, M; Badr, H; Gamal, M, 2022) |
| " Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels." | 2.82 | Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. ( Baea, M; Fleckenstein, LL; Kazura, JW; King, CL; Lombore, B; Maki, E; Sanuku, N; Satofan, S; Schmidt, MS; Siba, PM; Thomsen, EK; Weil, GJ, 2016) |
| " In the absence of alternative drugs, the use of higher or more frequent dosing with the existing drugs needs to be explored." | 2.80 | A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India. ( Dwibedi, B; Horton, J; Kar, SK; Kerketa, AS; Maharana, A; Mohanty, PC; Panda, SS; Ramachandran, CP, 2015) |
| " No serious adverse events occurred, and the majority of adverse events were mild in intensity (mainly headache, abdominal pain, diarrhoea and "other signs/symptoms")." | 2.78 | A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. ( Coulibaly, YI; Daou, A; Dicko, I; Doumbia, M; Haidara, FC; Horton, J; Keita, M; Keita, MM; Sankare, MH; Sow, SO; Whately-Smith, C, 2013) |
| " The treatment arms administered with DEC alone and DEC+ALB demonstrated long-term benefits in reducing microfilaraemia significantly (P<0." | 2.72 | Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years. ( Dash, AP; Mani, TR; Munirathinam, A; Rajendran, R; Reuben, R; Sunish, IP, 2006) |
| "The Global Program for Elimination of Lymphatic Filariasis calls for mass drug administration for endemic populations outside of sub-Saharan Africa with a single dose of diethylcarbamazine (DEC) and albendazole (Alb) annually for 4-6 years." | 2.71 | A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. ( Ahmed, ES; El Setouhy, M; Farid, HA; Helmy, H; Hussain, O; Kandil, AM; Ramzy, RM; Weil, GJ, 2004) |
| " Safety was assessed by monitoring if adverse events (AEs) over 5 days affected daily acivities." | 2.71 | Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India. ( Deshmukh, PR; Fleckenstein, L; Garg, BS; Gogtay, NJ; Ingole, NS; Kadam, VS; Karbwang, J; Kirodian, BG; Kshirsagar, NA; Lazdins-Helds, JK; Mehendale, AM; Rajgor, DD, 2004) |
| " Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed." | 2.70 | The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. ( Arun, SR; Fleckenstein, LL; John, A; Kumaraswami, V; Na-Bangchang, K; Shenoy, RK; Suma, TK, 2002) |
| "Onchocerciasis and lymphatic filariasis (LF) are human filarial diseases belonging to the group of neglected tropical diseases, leading to permanent and long-term disability in infected individuals in the endemic countries such as Africa and India." | 2.61 | Anti- ( Basri, H; Ching, SM; Hashim, HZ; Hoo, FK; Inche Mat, LN; Kamtchum-Tatuene, J; Mohamed, MH; Ramachandran, V; Sazlly Lim, SM; Wan Sulaiman, WA, 2019) |
| "Flubendazole (FBZ) was approved in 1980 for the treatment of gastrointestinal nematode infections in both veterinary and human medicine." | 2.61 | Flubendazole as a macrofilaricide: History and background. ( Geary, TG; Mackenzie, CD; Silber, SA, 2019) |
| "We included randomized controlled trials (RCTs) and cluster-RCTs that compared albendazole to placebo or no placebo, or compared albendazole combined with a microfilaricidal drug to a microfilaricidal drug alone, given to people known to have lymphatic filariasis or communities where lymphatic filariasis was known to be endemic." | 2.61 | Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis. ( Budhathoki, SS; Garner, P; Johnson, S; Macfarlane, CL; Richardson, M, 2019) |
| "To provide context for the results of a large-scale, international safety trial of MDA using triple drug therapy, we searched Ovid Medline for studies published from 1985-2017 that reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combination of these medications." | 2.58 | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. ( Andersen, BJ; Budge, PJ; Herbert, C; Weil, GJ, 2018) |
| "Approximately 15 million people with lymphatic filariasis (LF) live in Southeast Asia." | 2.46 | Elimination of lymphatic filariasis in Southeast Asia. ( Bergquist, R; Chayabejara, S; Duong, S; Hernandez, L; Sudomo, M; Wu, WP, 2010) |
| "The Global Programme to Eliminate Lymphatic Filariasis recommends albendazole in combination with other antifilarial drugs." | 2.43 | Albendazole for the control and elimination of lymphatic filariasis: systematic review. ( Addiss, D; Critchley, J; Ejere, H; Gamble, C; Garner, P; Gelband, H, 2005) |
| "Mass treatment with albendazole co-administered with another antifilarial drug is part of a global programme to eliminate lymphatic filariasis." | 2.43 | Albendazole for lymphatic filariasis. ( Addiss, D; Critchley, J; Ejere, H; Gamble, C; Garner, P; Gelband, H, 2005) |
| "For diethylcarbamazine-albendazole treatment the average mf loss was approximately 83% (ranging from 54% to 100% in the different studies) and worm-productivity loss was 100% (in all studies)." | 2.43 | Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. ( de Kraker, ME; Habbema, JD; Stolk, WA; van Oortmarssen, GJ, 2006) |
| "Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis." | 2.42 | Albendazole for lymphatic filariasis. ( Addiss, D; Critchley, J; Ejere, H; Gamble, C; Garner, P; Gelband, H, 2004) |
| "The pathogenesis of lymphatic filariasis has been a matter of debate for many decades." | 2.41 | Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. ( Dreyer, G; Figueredo-Silva, J; Norões, J; Piessens, WF, 2000) |
| " Both DEC and ivermectin show, as expected, an adverse event profile compatible with the destruction of microfilariae." | 2.41 | An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. ( Addiss, DG; Awadzi, K; Beach, MJ; Belizario, VY; Dunyo, SK; Espinel, M; Gyapong, JO; Horton, J; Hossain, M; Ismail, MM; Jayakody, RL; Lammie, PJ; Lazdins, JK; Makunde, W; Ottesen, EA; Richard-Lenoble, D; Selve, B; Shenoy, RK; Simonsen, PE; Wamae, CN; Weerasooriya, MV; Witt, C, 2000) |
| " The drug shows high variability in drug exposure in previous pharmacokinetic studies." | 1.91 | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis. ( Alshehri, A; Bala, V; Bjerum, CM; Chhonker, YS; Edi, C; John, LN; King, CL; Koudou, BG; Marks, M; Mitjà, O; Murry, DJ, 2023) |
| "We conducted a community-based, observational, cohort event monitoring study to compare the types, frequency, severity, and predictors of adverse events following dual versus triple therapy in 20,421 eligible residents." | 1.91 | Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study. ( Aklillu, E; Barry, A; Guantai, A; Khaemba, C; Kirui, E; Njenga, SM; Oluka, M; Omondi, WP; Parthasarathi, G, 2023) |
| " Pharmacokinetic parameters were determined using standard non-compartmental analysis methods." | 1.91 | Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis. ( Alshehri, A; Bala, V; Bjerum, C; Budge, PJ; Chhonker, YS; Fischer, PU; Gabo, TP; King, CL; Koudou, BG; Meïté, A; Murry, DJ; Ouattara, AF; Weil, GJ, 2023) |
| "We used the introduction of the Japanese encephalitis (JE) vaccine in India as an example to understand more fully the process of introducing any new clinical product in India." | 1.72 | Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin-Diethylcarbamazine-Albendazole for Lymphatic Filariasis Elimination. ( Ghosh, RS; Haldar, P; Jacobson, J, 2022) |
| "Among this group, the prevalence of lymphatic filariasis of the 14-65 years olds in 2009 was 35." | 1.72 | Step towards elimination of Wuchereria bancrofti in Southwest Tanzania 10 years after mass drug administration with Albendazole and Ivermectin. ( Chachage, M; Chiwerengo, N; Clowes, P; Debrah, A; Geldmacher, C; Haule, A; Hoelscher, M; Hoerauf, A; Horn, S; Kalinga, A; Kavishe, G; Kroidl, I; Lazarus, W; Maganga, L; Marandu, TF; Mhidze, J; Mnkai, J; Mosoba, M; Ngenya, A; Ntapara, E; Rieß, F; Saathoff, E; Urio, A, 2022) |
| " Age, underweight, and double dosing were associated with increase in ADE incidence, while gender and food intake were not associated with increase in ADE incidence." | 1.72 | Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana. ( Akrasi, W; Boye, A; Brah, AS; Essuman, MA; Osei, V, 2022) |
| "These results demonstrate a clear dose-response relationship for the effect of ALB on clearance of CFA and microfilaremia." | 1.62 | Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence. ( Awaca-Uvon, NP; Boussinesq, M; Campillo, JT; Chesnais, CB; Kuyangisa-Simuna, G; Louya, F; Missamou, F; Pion, SDS; Tambwe, JP; Weil, GJ, 2021) |
| "Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments." | 1.56 | Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis. ( Bah, Y; Baker, M; Batcho, W; Benjamin Didier, B; Bougma, R; Bougouma, C; Brady, M; Burgert-Brucker, CR; Coulibaly, YI; Doumbia, SS; Georges, N; Headland, M; Karim, MJ; Kraemer, J; Lemoine, JF; Marfo, B; Muheki, E; Mwingira, U; Ndayishimye, E; Nshala, A; Pangaribuan, HU; Rimal, P; Salissou, AB; Shoemaker, EA; Shott, J; Stelmach, R; Wijayanti, E; Yevstigneyeva, V; Zoerhoff, KL, 2020) |
| "Lymphedema is a public health problem in countries with lymphatic filariasis (LF) including Mali." | 1.56 | Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration. ( Colebunders, R; Coulibaly, ME; Coulibaly, SY; Coulibaly, YI; Diallo, AA; Diarra, Y; Dolo, H; Doumbia, S; Doumbia, SS; Konipo, FN; Nutman, TB; Sangare, M; Sangare, MB; Soumaoro, L, 2020) |
| " This paper aims to describe Samoa's experience with program coverage and adverse events (AEs) in the first round of triple-drug MDA." | 1.56 | A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018. ( Gass, K; Graves, PM; Kearns, T; Lau, CL; Mayfield, HJ; Naseri, T; Sheridan, S; Thomsen, R; Willis, GA, 2020) |
| "The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission." | 1.56 | A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery. ( Jacobson, JA; King, JD; Weil, GJ, 2020) |
| "Fear of adverse events (AEs) negatively affects compliance to mass drug administration (MDA) for lymphatic filariasis (LF) elimination program." | 1.56 | Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India. ( Krishnamoorthy, K; Kuttiatt, VS; Purushothaman, J; Somani, RK; Swaminathan, S; Weil, GJ, 2020) |
| "In contrast, Trichuris infection intensity was not significantly reduced by MDA (p = 0." | 1.56 | The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. ( Abdou, A; Awaca-Uvon, NP; Boussinesq, M; Chesnais, CB; Kunyu-Shako, B; Kuyangisa Simuna, G; Pion, SDS; Tambwe, JP; Vlaminck, J; Weil, GJ, 2020) |
| "Two coverage rates for MDA for lymphatic filariasis were subsequently calculated using the reported number treated divided by the total population from: 1) the pre-MDA register and 2) national census projections." | 1.51 | Are census data accurate for estimating coverage of a lymphatic filariasis MDA campaign? Results of a survey in Sierra Leone. ( Baker, M; Bisanzio, D; Chowdhury, D; Conteh, A; Hodges, MH; Kamara, W; Koroma, JB; Macarthy, F; Magbity, E; Samai, M; Sonnie, M; Toubali, EH; Zoerhoff, KL, 2019) |
| "Lymphatic filariasis is endemic in nine of the eleven Member States of the World Health Organization South East Asia Region." | 1.51 | How Thailand eliminated lymphatic filariasis as a public health problem. ( Boondej, P; Gopinath, D; Khuanyoung, N; Prempree, P; Ramaiah, KD; Rojanapanus, S; Santabutr, W; Thammapalo, S; Toothong, T, 2019) |
| "Conventional oral therapy of lymphatic filariasis drugs is only effective to kill microfilariae in the bloodstream, but is often ineffective to kill adult filarial (macrofilariae) in the complex anatomy of the lymphatic system." | 1.51 | Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. ( Anjani, QK; Donnelly, RF; McCarthy, HO; McCrudden, MTC; Permana, AD; Ramadon, D; Tekko, IA, 2019) |
| "Current WHO recommendations for lymphatic filariasis (LF) surveillance advise programs to implement activities to monitor for new foci of transmission after stopping mass drug administration (MDA)." | 1.48 | Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa. ( Fuimaono, S; Gass, K; Hamlin, KL; Kubofcik, J; Lammie, PJ; Nutman, TB; Robinson, K; Seespesara, M; Tufa, J; Wiegand, RE; Won, KY, 2018) |
| "Endemicity of lymphatic filariasis (LF) in Cambodia was proven in 1956 when microfilariae were detected in mosquitos in the Kratié province." | 1.48 | How elimination of lymphatic filariasis as a public health problem in the Kingdom of Cambodia was achieved. ( Brady, MA; Char, MC; Huy, R; Khieu, V; Muth, S; Odermatt, P; Or, V; Ramaiah, KD; Sidwell, J; Tep, C; Tsuyuoka, R; Yajima, A, 2018) |
| " When distributing microfilaricides however, considerable care is needed to minimise the risk of severe adverse events (SAEs) in areas that are co-endemic for onchocerciasis or LF and loiasis." | 1.48 | Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. ( Basáñez, MG; Cano, J; O'Hanlon, SJ; Pullan, RL; Rebollo, MP; Tekle, AH; Wanji, S; Zouré, HG, 2018) |
| "Control of lymphatic filariasis (LF) in most of the sub-Saharan African countries is based on annual mass drug administration (MDA) using a combination of ivermectin and albendazole." | 1.48 | Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration. ( Bockarie, M; Derua, YA; Jones, C; Malecela, MN; Ngasala, B; Reimer, L; Tarimo, D, 2018) |
| "Lymphatic filariasis is widely endemic in Myanmar." | 1.48 | The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar. ( Aye, NN; Bradbury, RS; Dickson, BFR; Douglass, J; Graves, PM; McBride, WJ; Nwe, TW; Shwe, M; Wai, T; Win, SS, 2018) |
| "A baseline survey in 2007-2008 found lymphatic filariasis (LF) to be endemic in Sierra Leone in all 14 districts and co-endemic with onchocerciasis in 12 districts." | 1.48 | Progress on elimination of lymphatic filariasis in Sierra Leone. ( Bah, M; Conteh, A; Hodges, MH; Koroma, JB; Paye, J; Sesay, S; Sonnie, M; Zhang, Y, 2018) |
| "There is the low-level persistence of bancroftian filariasis and re-emergence of brugian filariasis in the Gampaha District, Sri Lanka." | 1.48 | Human infection with sub-periodic Brugia spp. in Gampaha District, Sri Lanka: a threat to filariasis elimination status? ( de Silva, NR; Mallawarachchi, CH; Mallawarachchi, SMNSM; Nilmini Chandrasena, TGA; Premaratna, R, 2018) |
| "Lymphatic filariasis is targeted for elimination as a public health problem by 2020." | 1.46 | Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. ( Hollingsworth, TD; Irvine, MA; Michael, E; Singh, BK; Smith, ME; Stolk, WA; Subramanian, S; Weil, GJ, 2017) |
| "The Global Programme to Eliminate Lymphatic Filariasis (LF) aims to eliminate the disease as a public health problem by 2020 by conducting mass drug administration (MDA) and controlling morbidity." | 1.46 | Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. ( Andreosso, A; Fuimaono, S; Graves, PM; Lau, CL; Roineau, M; Ryan, S; Sheridan, S; Tufa, J, 2017) |
| "The Tanzanian National Lymphatic Filariasis Elimination Programme reported annual treatment coverage for Rufiji District ranging from 54." | 1.46 | Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets ( Derua, YA; Jones, C; Malecela, MN; Ngasalla, B; Tarimo, D, 2017) |
| "Our aim was to assess the lymphatic filariasis situation, following mass drug administration." | 1.43 | Surveillance for transmission of lymphatic filariasis in Colombo and Gampaha districts of Sri Lanka following mass drug administration. ( Chandrasena, NT; de Silva, NR; Premaratna, R; Samarasekera, DS, 2016) |
| "The prevalence of lymphatic filariasis in adults above 18 years was 42." | 1.43 | Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. ( Clowes, P; Haule, A; Hoelscher, M; Hoerauf, A; Kowuor, D; Kroidl, I; Löscher, T; Maboko, L; Mabuye, J; Maganga, L; Makunde, WH; Malecela, MN; Mgeni, N; Mviombo, P; Mwingira, U; Pitter, B; Saathof, E, 2016) |
| "As the Global Programme to Eliminate Lymphatic Filariasis (LF) approaches its 2020 goal, an increasing number of districts will enter the endgame phase where drug coverage rates from mass drug administration (MDA) are used to assess whether MDA can be stopped." | 1.43 | Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys. ( Bradley, M; Damayanti, R; Krentel, A; Lynam, T; Suharno, N; Titaley, CR, 2016) |
| " Albendazole (ALB) is being administered with diethyl carbamazine (DEC) in filariasis endemic areas to eliminate lymphatic filariasis (LF) and helminth infections." | 1.42 | Impact on prevalence of intestinal helminth infection in school children administered with seven annual rounds of diethyl carbamazine (DEC) with albendazole. ( Kalimuthu, M; Kumar, VA; Munirathinam, A; Nagaraj, J; Rajendran, R; Sunish, IP; Tyagi, BK, 2015) |
| "Under the Global Programme to Eliminate Lymphatic Filariasis (LF), mass drug administration (MDA) is being implemented in Tamil Nadu, south India, by the State health machinery." | 1.40 | Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations. ( Ashok Kumar, V; Kalimuthu, M; Munirathinam, A; Sunish, IP; Tyagi, BK, 2014) |
| "Lymphatic filariasis is still endemic in many parts of India." | 1.40 | Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA). ( Kumar, A; Sachan, P, 2014) |
| "When the Global Programme to Eliminate Lymphatic Filariasis was launched in 2000, diagnostic tools for LF were limited to clinical examination, detection of microfilaria (MF) by microscopy in night blood samples and detection of antibodies to native-antigen preparations." | 1.40 | Shrinking the lymphatic filariasis map: update on diagnostic tools for mapping and transmission monitoring. ( Bockarie, MJ; Rebollo, MP, 2014) |
| "Our current strategy against lymphatic filariasis which combines annual mass drug administration, systematic treatment of antigenemic and microfilaraemic patients, and vector control; failed to reach the target of 1% prevalence." | 1.39 | Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment. ( Musso, D, 2013) |
| "Control of lymphatic filariasis (LF) in most countries of sub-Saharan Africa is based on annual mass drug administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission." | 1.39 | Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission. ( Derua, YA; Kisinza, WN; Magesa, SM; Malecela, MN; Pedersen, EM; Simonsen, PE, 2013) |
| "The approaches are applied to a lymphatic filariasis study that motivated this study." | 1.39 | Semiparametric regression analysis of clustered interval-censored failure time data with informative cluster size. ( Sun, J; Zhang, X, 2013) |
| "Baseline lymphatic filariasis microfilarial age-prevalence data from three geographically distinct endemic regions, across which the major vector populations implicated in parasite transmission also differed, were used to fit and calibrate the relevant vector-specific filariasis transmission models." | 1.36 | Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. ( Bockarie, M; Gambhir, M; Kazura, J; Michael, E; Remais, J; Spear, R; Tisch, D, 2010) |
| "Lymphocele is a well-known complication of renal transplantation." | 1.36 | Post-kidney transplantation lymphocele due to a lymphatic filariasis. ( Chebil, M; Derouiche, A; El Atat, R; Ezzeddine, A; Garbouj, N; Khaled, A; Mechri, M, 2010) |
| "Nearly 45% of people living at risk for lymphatic filariasis (LF) worldwide live in India." | 1.36 | Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. ( Cantey, PT; Fox, LM; Rao, G; Rout, J; Williamson, J, 2010) |
| "The combined effect of the Lymphatic Filariasis Elimination Programme (LFEP) and the National Schistosomiasis and Soil-transmitted Helminthiasis Control Programme (NSSCP) on soil-transmitted helminthiasis (STH) was evaluated." | 1.35 | The combined effect of the Lymphatic Filariasis Elimination Programme and the Schistosomiasis and Soil-transmitted Helminthiasis Control Programme on soil-transmitted helminthiasis in schoolchildren in Tanzania. ( Magnussen, P; Massa, K; Ndawi, B; Ntakamulenga, R; Olsen, A; Sheshe, A, 2009) |
| "punctulatus vector." | 1.35 | The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. ( Bockarie, MJ; Kastens, W; Kazura, JW; King, CL; Laney, SJ; Susapu, M; Weil, GJ; Williams, SA, 2008) |
| "Lymphatic filariasis is increasingly viewed as the result of an infection that is often acquired in childhood." | 1.35 | Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. ( Dhananjayan, G; Kumaraswami, V; Padma, S; Rahmah, N; Shenoy, RK; Suma, TK, 2009) |
| "Lymphatic filariasis is targeted to be eliminated globally, at least as a public-health problem, by 2020." | 1.34 | Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka. ( Bradley, MH; Gunawardena, GS; Ismail, MM; Karunaweera, ND, 2007) |
| "Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF." | 1.34 | National mass drug administration costs for lymphatic filariasis elimination. ( Aikins, M; Amarillo, ML; Belizario, VY; Brady, MA; Garshong, B; Goldman, AS; Guisinger, VH; Gyapong, J; Haddix, AC; Kabali, C; Kamal, HA; Kanjilal, S; Kyelem, D; Lizardo, J; Malecela, M; Mubyazi, G; Nitièma, PA; Ottesen, EA; Ramzy, RM; Rheingans, R; Streit, TG; Wallace, A, 2007) |
| " We wish to show that this new regimen does not increase the rate of a rare serious adverse event (SAE) compared to the old regimen." | 1.34 | Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls. ( Fay, MP; Huang, CY; Twum-Danso, NA, 2007) |
| "Severe adverse reactions to lymphatic filariasis treatment using DEC with or without albendazole are uncommon." | 1.32 | Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. ( Addiss, DG; Beach, MJ; Lafontant, J; Lammie, J; Lammie, PJ; McLaughlin, SI; Michel, MC; Radday, J; Rheingans, R, 2003) |
| "A two-arm community-based lymphatic filariasis elimination trial is being carried out in Tamil Nadu state, India to assess the effect of 2 annual single-dose mass drug administrations of diethylcarbamazine + albendazole (DEC + ALB) on microfilaraemia and antigenaemia in one arm, and diethylcarbamazine(DEC) alone in the other arm." | 1.32 | Impact of two annual single-dose mass drug administrations with diethylcarbamazine alone or in combination with albendazole on Wuchereria bancrofti microfilaraemia and antigenaemia in south India. ( Abdullah, SM; Arunachalam, N; Mani, TR; Munirathinam, A; Rajendran, R; Satyanarayana, K; Sunish, IP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.50) | 18.2507 |
| 2000's | 83 (31.20) | 29.6817 |
| 2010's | 115 (43.23) | 24.3611 |
| 2020's | 64 (24.06) | 2.80 |
| Authors | Studies |
|---|---|
| Niles, RA | 1 |
| Thickstun, CR | 1 |
| Cox, H | 1 |
| Dilliott, D | 2 |
| Burgert-Brucker, CR | 2 |
| Harding-Esch, EM | 1 |
| Clementson, N | 1 |
| Sampson, A | 1 |
| Alexandre, JS | 1 |
| Morice Trejos, AC | 1 |
| Scholte, RGC | 1 |
| Krentel, A | 6 |
| Kaliappan, S | 1 |
| Ramanujam, K | 1 |
| Manuel, M | 1 |
| Farzana, J | 1 |
| Janagaraj, V | 1 |
| Laxmanan, S | 1 |
| Muliyil, J | 1 |
| Sarkar, R | 1 |
| Kang, G | 1 |
| Walson, J | 1 |
| Ajjampur, S | 1 |
| Eneanya, OA | 4 |
| Gankpala, L | 2 |
| Goss, CW | 11 |
| Bolay, FK | 4 |
| Weil, GJ | 47 |
| Fischer, PU | 16 |
| Pion, SDS | 5 |
| Chesnais, CB | 8 |
| Louya, F | 3 |
| Boussinesq, M | 7 |
| Missamou, F | 4 |
| Lupenza, ET | 1 |
| Gasarasi, DB | 1 |
| Minzi, OM | 1 |
| Abuelazm, MT | 1 |
| Abdelazeem, B | 1 |
| Badr, H | 1 |
| Gamal, M | 1 |
| Ashraf, M | 1 |
| Abd-Elsalam, S | 1 |
| Tavul, L | 3 |
| Laman, M | 4 |
| Howard, C | 2 |
| Kotty, B | 2 |
| Samuel, A | 2 |
| Bjerum, C | 2 |
| O'Brian, K | 2 |
| Kumai, S | 2 |
| Amuga, M | 1 |
| Lorry, L | 2 |
| Kerry, Z | 2 |
| Kualawi, M | 1 |
| Karl, S | 2 |
| Makita, L | 2 |
| John, LN | 2 |
| Bieb, S | 2 |
| Wangi, J | 2 |
| Tisch, DJ | 2 |
| Pomat, W | 1 |
| King, CL | 20 |
| Robinson, LJ | 6 |
| Cheema, HA | 1 |
| Shahid, A | 1 |
| Ghosh, RS | 1 |
| Haldar, P | 1 |
| Jacobson, J | 3 |
| King, JD | 5 |
| Rainima-Qaniuci, M | 1 |
| Lepaitai, HB | 1 |
| Bhagirov, R | 1 |
| Padmasiri, E | 1 |
| Naseri, T | 2 |
| Thomsen, R | 2 |
| Won, KY | 2 |
| Brant, TA | 1 |
| Dodd, E | 1 |
| Nua, MT | 1 |
| Utu, F | 1 |
| Tufa, A | 1 |
| Chutaro, E | 1 |
| Camacho, J | 1 |
| Suiaunoa-Scanlan, L | 1 |
| Thean, LJ | 1 |
| Mani, J | 1 |
| Hardy, M | 5 |
| Samuela, J | 5 |
| Romani, L | 3 |
| Kaldor, J | 1 |
| Steer, AC | 4 |
| Faktaufon, D | 1 |
| Bechu, V | 1 |
| Naqio, F | 1 |
| Sosene, V | 1 |
| Sekihara, M | 1 |
| Otaki, J | 1 |
| Buhagiar, TS | 1 |
| Yajima, A | 2 |
| Tripathi, B | 1 |
| Roy, N | 2 |
| Dhingra, N | 1 |
| Jambulingam, P | 7 |
| Subramanian, S | 8 |
| Krishnamoorthy, K | 7 |
| Supali, T | 7 |
| Fischer, P | 4 |
| Dubray, C | 2 |
| Fayette, C | 1 |
| Lemoine, JF | 5 |
| King, C | 1 |
| Momolu, AT | 1 |
| Nyan, ES | 1 |
| Gray, EB | 1 |
| Fischer, K | 2 |
| Curtis, K | 2 |
| Timinao, L | 1 |
| Howard, SC | 1 |
| John, L | 1 |
| Albert, JM | 1 |
| Payne, M | 1 |
| Bjerum, CM | 6 |
| Mandal, AK | 1 |
| Jana, JK | 1 |
| Gayen, S | 1 |
| Pal, AC | 1 |
| Anagbogu, IN | 1 |
| Saka, YA | 4 |
| Surakat, OA | 1 |
| Okoronkwo, C | 1 |
| Davies, E | 3 |
| Oyale, P | 1 |
| Ekpo, UF | 1 |
| Amazigo, UV | 1 |
| Barbre, K | 1 |
| Igbe, M | 1 |
| Nyior, A | 1 |
| Jacob, SM | 1 |
| Gideon Nteun, U | 1 |
| Abubakar Umar, Z | 1 |
| Kumar, V | 1 |
| Mishra, A | 1 |
| Yadav, AK | 1 |
| Rathaur, S | 1 |
| Singh, A | 1 |
| McLure, A | 2 |
| Graves, PM | 5 |
| Lau, C | 1 |
| Shaw, C | 2 |
| Glass, K | 2 |
| Mnkai, J | 1 |
| Marandu, TF | 1 |
| Mhidze, J | 1 |
| Urio, A | 1 |
| Maganga, L | 2 |
| Haule, A | 2 |
| Kavishe, G | 1 |
| Ntapara, E | 1 |
| Chiwerengo, N | 1 |
| Clowes, P | 2 |
| Horn, S | 1 |
| Mosoba, M | 1 |
| Lazarus, W | 1 |
| Ngenya, A | 1 |
| Kalinga, A | 1 |
| Debrah, A | 1 |
| Rieß, F | 1 |
| Saathoff, E | 1 |
| Geldmacher, C | 1 |
| Hoerauf, A | 8 |
| Hoelscher, M | 2 |
| Chachage, M | 1 |
| Kroidl, I | 2 |
| Coulibaly, YI | 8 |
| Sangare, M | 3 |
| Dolo, H | 3 |
| Soumaoro, L | 3 |
| Coulibaly, SY | 4 |
| Dicko, I | 3 |
| Diabaté, AF | 1 |
| Diarra, L | 1 |
| Coulibaly, ME | 3 |
| Doumbia, SS | 5 |
| Diallo, AA | 5 |
| Dembele, M | 1 |
| Koudou, BG | 11 |
| Bockarie, MJ | 7 |
| Kelly-Hope, LA | 2 |
| Klion, AD | 4 |
| Nutman, TB | 7 |
| Akrasi, W | 1 |
| Brah, AS | 1 |
| Essuman, MA | 1 |
| Osei, V | 1 |
| Boye, A | 1 |
| Sabesan, S | 2 |
| Hoti, SL | 4 |
| Srividya, A | 2 |
| Jain, T | 1 |
| Kumar, A | 2 |
| Rahi, M | 2 |
| Stolk, WA | 8 |
| Coffeng, LE | 2 |
| Hollingsworth, TD | 4 |
| Méité, A | 6 |
| Michael, E | 7 |
| Prada, JM | 4 |
| Caja Rivera, RM | 2 |
| Sharma, S | 2 |
| Touloupou, P | 3 |
| de Vlas, SJ | 5 |
| Serme, M | 1 |
| Zida, A | 1 |
| Bougma, R | 2 |
| Kima, A | 1 |
| Nassa, C | 1 |
| Ouedraogo, M | 1 |
| Kabre, C | 1 |
| Zoromé, H | 1 |
| Guire, I | 1 |
| Nare, D | 1 |
| Bougouma, C | 2 |
| Lau, CL | 3 |
| Opoku, NO | 1 |
| Doe, F | 1 |
| Dubben, B | 1 |
| Fetcho, N | 1 |
| Gordor, S | 1 |
| Gyasi, ME | 1 |
| Hong, AR | 1 |
| Kanza, E | 1 |
| Laryea, R | 1 |
| Lew, D | 5 |
| Seidu, MA | 1 |
| Alshehri, A | 2 |
| Chhonker, YS | 3 |
| Bala, V | 2 |
| Edi, C | 2 |
| Mitjà, O | 1 |
| Marks, M | 2 |
| Murry, DJ | 3 |
| Greene, SE | 1 |
| Huang, Y | 1 |
| Curtis, KC | 1 |
| McPherson, S | 1 |
| Solomon, AW | 1 |
| Seife, F | 2 |
| Solomon, H | 1 |
| Gebre, T | 1 |
| Mabey, DCW | 1 |
| Khaemba, C | 1 |
| Barry, A | 1 |
| Omondi, WP | 2 |
| Kirui, E | 1 |
| Oluka, M | 1 |
| Parthasarathi, G | 1 |
| Njenga, SM | 3 |
| Guantai, A | 1 |
| Aklillu, E | 1 |
| Ouattara, AF | 5 |
| Gabo, TP | 1 |
| Budge, PJ | 4 |
| Hassen, M | 1 |
| Mohammed, A | 1 |
| Endeshaw, T | 1 |
| Seid, T | 1 |
| Samuel, F | 1 |
| Asmare, T | 1 |
| Birhanu, H | 1 |
| Bekele, F | 1 |
| Yayeh, A | 1 |
| Tamiru, M | 1 |
| Meribo, K | 1 |
| Tadesse, Z | 1 |
| Griswold, E | 2 |
| Katabarwa, M | 2 |
| Richards, F | 3 |
| Noland, GS | 5 |
| Gabo, PT | 1 |
| Biritwum, NK | 5 |
| Frempong, KK | 1 |
| Verver, S | 1 |
| Odoom, S | 2 |
| Alomatu, B | 2 |
| Asiedu, O | 2 |
| Kontoroupis, P | 2 |
| Yeboah, A | 2 |
| Hervie, ET | 1 |
| Marfo, B | 3 |
| Boakye, DA | 5 |
| Gyapong, JO | 4 |
| Chami, GF | 1 |
| Kabatereine, NB | 1 |
| Tukahebwa, EM | 1 |
| Wan Sulaiman, WA | 1 |
| Kamtchum-Tatuene, J | 1 |
| Mohamed, MH | 1 |
| Ramachandran, V | 1 |
| Ching, SM | 1 |
| Sazlly Lim, SM | 1 |
| Hashim, HZ | 1 |
| Inche Mat, LN | 1 |
| Hoo, FK | 1 |
| Basri, H | 1 |
| Flynn, AF | 1 |
| Joyce, MG | 1 |
| Taylor, RT | 1 |
| Bennuru, S | 1 |
| Lindrose, AR | 1 |
| Sterling, SL | 1 |
| Morris, CP | 1 |
| Mitre, E | 1 |
| Andersen, BJ | 3 |
| Rosa, BA | 1 |
| Kupritz, J | 1 |
| Serge, T | 1 |
| Hertz, MI | 1 |
| Mitreva, M | 1 |
| Aboulaye, M | 2 |
| Kouadio, O | 2 |
| Marius, VK | 2 |
| Permana, AD | 1 |
| Tekko, IA | 1 |
| McCrudden, MTC | 1 |
| Anjani, QK | 1 |
| Ramadon, D | 1 |
| McCarthy, HO | 1 |
| Donnelly, RF | 1 |
| Kuttiatt, VS | 2 |
| Somani, RK | 2 |
| Swaminathan, S | 2 |
| Purushothaman, J | 1 |
| Kamara, W | 1 |
| Zoerhoff, KL | 3 |
| Toubali, EH | 1 |
| Hodges, MH | 4 |
| Bisanzio, D | 1 |
| Chowdhury, D | 1 |
| Sonnie, M | 4 |
| Magbity, E | 1 |
| Samai, M | 1 |
| Conteh, A | 4 |
| Macarthy, F | 1 |
| Baker, M | 4 |
| Koroma, JB | 4 |
| Konipo, FN | 1 |
| Sangare, MB | 1 |
| Diarra, Y | 1 |
| Doumbia, S | 1 |
| Colebunders, R | 1 |
| Kama, M | 2 |
| Tuicakau, M | 2 |
| Whitfeld, MJ | 2 |
| Grobler, AC | 2 |
| Kaldor, JM | 2 |
| Shriram, AN | 2 |
| Premkumar, A | 1 |
| De, A | 1 |
| Paul, SK | 1 |
| Vijayachari, P | 2 |
| Eigege, A | 10 |
| Adelamo, SE | 4 |
| Nwodu, K | 1 |
| Sallau, A | 2 |
| Umaru, J | 8 |
| Mancha, BS | 2 |
| Danboyi, J | 4 |
| Kadimbo, JA | 1 |
| Anagbogu, I | 2 |
| Miri, ES | 5 |
| Richards, FO | 8 |
| Kazura, JW | 5 |
| Headland, M | 1 |
| Shoemaker, EA | 1 |
| Stelmach, R | 1 |
| Karim, MJ | 1 |
| Batcho, W | 2 |
| Benjamin Didier, B | 1 |
| Georges, N | 1 |
| Pangaribuan, HU | 1 |
| Wijayanti, E | 1 |
| Rimal, P | 1 |
| Salissou, AB | 1 |
| Bah, Y | 1 |
| Mwingira, U | 2 |
| Nshala, A | 1 |
| Muheki, E | 1 |
| Shott, J | 1 |
| Yevstigneyeva, V | 1 |
| Ndayishimye, E | 1 |
| Kraemer, J | 1 |
| Brady, M | 1 |
| Dubray, CL | 1 |
| Sircar, AD | 1 |
| Beau de Rochars, VM | 2 |
| Bogus, J | 3 |
| Direny, AN | 6 |
| Ernest, JR | 1 |
| Fayette, CR | 2 |
| Hast, M | 1 |
| Pavilus, GE | 1 |
| Sabin, DF | 1 |
| Wiegand, RE | 2 |
| Awaca-Uvon, NP | 4 |
| Vlaminck, J | 2 |
| Abdou, A | 1 |
| Kunyu-Shako, B | 1 |
| Kuyangisa Simuna, G | 1 |
| Tambwe, JP | 4 |
| Al-Kubati, AS | 1 |
| Al-Samie, AR | 1 |
| Al-Kubati, S | 1 |
| Ramzy, RMR | 1 |
| Campillo, JT | 3 |
| Kuyangisa-Simuna, G | 3 |
| Loukouri, A | 1 |
| N'Goran, EK | 1 |
| Sankari, T | 1 |
| Pani, SP | 1 |
| Das, PK | 5 |
| Willis, GA | 1 |
| Mayfield, HJ | 1 |
| Kearns, T | 1 |
| Gass, K | 2 |
| Sheridan, S | 2 |
| Ottesen, EA | 6 |
| Horton, J | 7 |
| Jacobson, JA | 2 |
| Bah, YM | 1 |
| Paye, J | 2 |
| Bah, MS | 1 |
| Redwood-Sawyerr, V | 1 |
| Veinoglou, A | 1 |
| Zhang, Y | 3 |
| Njomo, DW | 2 |
| Kimani, BW | 1 |
| Kibe, LW | 1 |
| Okoyo, C | 1 |
| Sultani, HM | 1 |
| Raju, HKK | 1 |
| Suryaprakash, MK | 1 |
| Dwivedi, GP | 1 |
| Basker, N | 1 |
| Beau de Rochars, M | 1 |
| Ga, AL | 1 |
| Mallya, S | 1 |
| Schechtman, KB | 1 |
| Andersen, B | 1 |
| Djuardi, Y | 2 |
| Christian, M | 1 |
| Iskandar, E | 1 |
| Alfian, R | 1 |
| Maylasari, R | 1 |
| Destani, Y | 1 |
| Lomiga, A | 1 |
| Minggu, D | 1 |
| Chabot, EB | 1 |
| Pion, SD | 2 |
| Gonzales, M | 1 |
| Mariano, EF | 1 |
| Blount, S | 2 |
| de Souza, DK | 4 |
| Hervie, TE | 1 |
| Mensah, EO | 1 |
| Yikpotey, P | 1 |
| Molyneux, D | 2 |
| Modi, A | 1 |
| Gamit, S | 1 |
| Jesalpura, BS | 1 |
| Kurien, G | 1 |
| Kosambiya, JK | 1 |
| Jones, C | 2 |
| Ngasalla, B | 1 |
| Derua, YA | 4 |
| Tarimo, D | 2 |
| Malecela, MN | 6 |
| Nana-Djeunga, HC | 1 |
| Tchouakui, M | 1 |
| Njitchouang, GR | 1 |
| Tchatchueng-Mbougua, JB | 1 |
| Nwane, P | 1 |
| Domche, A | 1 |
| Bopda, J | 2 |
| Mbickmen-Tchana, S | 1 |
| Akame, J | 1 |
| Tarini, A | 1 |
| Epée, E | 1 |
| Biholong, BD | 1 |
| Tougoue, JJ | 1 |
| Kabore, A | 1 |
| Njiokou, F | 1 |
| Kamgno, J | 1 |
| Ojha, CR | 1 |
| Joshi, B | 1 |
| Kc, KP | 1 |
| Dumre, SP | 1 |
| Yogi, KK | 1 |
| Bhatta, B | 1 |
| Adhikari, T | 1 |
| Crowley, K | 2 |
| Marasini, BR | 1 |
| Evans, DS | 3 |
| Mancha, B | 1 |
| Okoeguale, B | 3 |
| Griswold, EP | 1 |
| Kshirsagar, NA | 2 |
| Gogtay, NJ | 2 |
| Garg, BS | 2 |
| Deshmukh, PR | 2 |
| Rajgor, DD | 2 |
| Kadam, VS | 2 |
| Thakur, PA | 1 |
| Gupta, A | 1 |
| Ingole, NS | 2 |
| Lazdins-Helds, JK | 2 |
| Owusu, IO | 1 |
| Otchere, J | 3 |
| Adimazoya, M | 1 |
| Frempong, K | 1 |
| Ahorlu, CS | 3 |
| Wilson, MD | 3 |
| Kanamitie, JN | 1 |
| Aboagye-Antwi, F | 2 |
| Kwansa-Bentum, B | 2 |
| Ryan, S | 1 |
| Roineau, M | 1 |
| Andreosso, A | 1 |
| Fuimaono, S | 2 |
| Tufa, J | 2 |
| Adu-Amankwah, S | 1 |
| Mensah, SK | 1 |
| Larbi, IA | 1 |
| Mensah, GE | 1 |
| Kar, SK | 4 |
| Dwibedi, B | 2 |
| Das, BK | 1 |
| Agrawala, BK | 1 |
| Ramachandran, CP | 2 |
| Rao, RU | 4 |
| Samarasekera, SD | 4 |
| Nagodavithana, KC | 4 |
| Dassanayaka, TDM | 2 |
| Punchihewa, MW | 3 |
| Ranasinghe, USB | 3 |
| Luroni, LT | 1 |
| Gabriel, M | 1 |
| Tukahebwa, E | 1 |
| Onapa, AW | 1 |
| Tinkitina, B | 1 |
| Tukesiga, E | 1 |
| Nyaraga, M | 1 |
| Auma, AM | 1 |
| Habomugisha, P | 1 |
| Byamukama, E | 1 |
| Oguttu, D | 1 |
| Unnasch, TR | 2 |
| Mallawarachchi, CH | 1 |
| Nilmini Chandrasena, TGA | 1 |
| Premaratna, R | 2 |
| Mallawarachchi, SMNSM | 1 |
| de Silva, NR | 4 |
| Cano, J | 1 |
| Basáñez, MG | 1 |
| O'Hanlon, SJ | 1 |
| Tekle, AH | 1 |
| Wanji, S | 1 |
| Zouré, HG | 1 |
| Rebollo, MP | 3 |
| Pullan, RL | 1 |
| Khieu, V | 1 |
| Or, V | 1 |
| Tep, C | 1 |
| Odermatt, P | 1 |
| Tsuyuoka, R | 1 |
| Char, MC | 1 |
| Brady, MA | 3 |
| Sidwell, J | 1 |
| Huy, R | 1 |
| Ramaiah, KD | 4 |
| Muth, S | 1 |
| Robinson, K | 1 |
| Hamlin, KL | 1 |
| Seespesara, M | 1 |
| Kubofcik, J | 3 |
| Lammie, PJ | 8 |
| Saeed, M | 1 |
| Faisal, SM | 1 |
| Ahmad, I | 1 |
| Kausar, MA | 1 |
| Alam, MJ | 1 |
| Khan, S | 1 |
| Mustafa, H | 1 |
| Khan, AM | 1 |
| Herbert, C | 1 |
| Smith, ME | 2 |
| de Vos, AS | 1 |
| Irvine, MA | 2 |
| Brown, P | 1 |
| Kloek, M | 1 |
| Sesay, S | 2 |
| Bah, M | 1 |
| Ityonzughul, C | 1 |
| Emukah, E | 1 |
| Kadiri, S | 1 |
| Adelamo, S | 1 |
| Ugbadamu, P | 1 |
| Ikogho, C | 1 |
| Mendis, D | 1 |
| Garchitorena, A | 1 |
| Raza-Fanomezanjanahary, EM | 1 |
| Mioramalala, SA | 1 |
| Ratsimbasoa, CA | 1 |
| Ramarosata, H | 1 |
| Bonds, MH | 1 |
| Rabenantoandro, H | 1 |
| Suamani, J | 1 |
| Sanuku, N | 3 |
| Cheng, YC | 1 |
| Satofan, S | 2 |
| Mancuso, B | 1 |
| Siba, PM | 3 |
| Dickson, BFR | 1 |
| Aye, NN | 1 |
| Nwe, TW | 1 |
| Wai, T | 1 |
| Win, SS | 1 |
| Shwe, M | 1 |
| Douglass, J | 1 |
| Bradbury, RS | 1 |
| McBride, WJ | 1 |
| Ngasala, B | 1 |
| Reimer, L | 1 |
| Bockarie, M | 3 |
| Minetti, C | 1 |
| Tettevi, EJ | 1 |
| Mechan, F | 1 |
| Idun, B | 1 |
| Osei-Atweneboana, MY | 1 |
| Reimer, LJ | 1 |
| Macfarlane, CL | 1 |
| Budhathoki, SS | 1 |
| Johnson, S | 1 |
| Richardson, M | 1 |
| Garner, P | 4 |
| Geary, TG | 1 |
| Mackenzie, CD | 1 |
| Silber, SA | 1 |
| Sarfo, B | 1 |
| Nortey, PA | 1 |
| Onakpoya, IJ | 1 |
| Penali, LK | 1 |
| Ritter, M | 1 |
| Osei-Mensah, J | 1 |
| Debrah, LB | 1 |
| Kwarteng, A | 1 |
| Mubarik, Y | 1 |
| Debrah, AY | 2 |
| Pfarr, K | 2 |
| Layland, LE | 1 |
| Rojanapanus, S | 1 |
| Toothong, T | 1 |
| Boondej, P | 1 |
| Thammapalo, S | 1 |
| Khuanyoung, N | 1 |
| Santabutr, W | 1 |
| Prempree, P | 1 |
| Gopinath, D | 1 |
| Boko-Collins, PM | 1 |
| Ogouyemi-Hounto, A | 1 |
| Adjinacou-Badou, EG | 1 |
| Gbaguidi-Saizonou, L | 1 |
| Dossa, NI | 1 |
| Dare, A | 1 |
| Ibikounle, M | 1 |
| Cohn, DA | 1 |
| Ravi, M | 1 |
| Nandha, B | 1 |
| Sunish, IP | 14 |
| Sivan, A | 1 |
| Kartick, C | 1 |
| Saha, BP | 1 |
| Keita, M | 1 |
| Keita, MM | 1 |
| Doumbia, M | 1 |
| Daou, A | 1 |
| Haidara, FC | 1 |
| Sankare, MH | 1 |
| Whately-Smith, C | 1 |
| Sow, SO | 1 |
| Musso, D | 1 |
| Abd Elaziz, KM | 2 |
| El-Setouhy, M | 2 |
| Bradley, MH | 5 |
| Ramzy, RM | 6 |
| Simonsen, PE | 4 |
| Kisinza, WN | 1 |
| Magesa, SM | 2 |
| Pedersen, EM | 2 |
| Zhang, X | 1 |
| Sun, J | 1 |
| Kal, A | 3 |
| Miri, E | 5 |
| Mafuyai, H | 3 |
| Chuwang, YS | 1 |
| Danjuma, G | 1 |
| Patterson, AE | 1 |
| Rakers, L | 2 |
| Eddy, BA | 1 |
| Blackstock, AJ | 1 |
| Williamson, JM | 1 |
| Addiss, DG | 8 |
| Streit, TG | 6 |
| Fox, LM | 3 |
| Stanton, MC | 2 |
| Molyneux, DH | 9 |
| Kyelem, D | 3 |
| Bougma, RW | 1 |
| Munirathinam, A | 12 |
| Kalimuthu, M | 5 |
| Ashok Kumar, V | 3 |
| Tyagi, BK | 8 |
| Schmidt, MS | 2 |
| Thomsen, EK | 2 |
| Fleckenstein, L | 2 |
| Sachan, P | 1 |
| Rajendran, R | 10 |
| Nagaraj, J | 4 |
| Alphonsus, K | 1 |
| Gonzales-Peralta, C | 1 |
| Adamani, W | 1 |
| Pede, E | 2 |
| Umbugadu, C | 1 |
| Saka, Y | 1 |
| Kisoka, WJ | 1 |
| Tersbøl, BP | 1 |
| Mushi, DL | 1 |
| Meyrowitsch, DW | 1 |
| Wijegunawardana, AD | 1 |
| Premakumara, WD | 1 |
| Perera, SN | 1 |
| Settinayake, S | 1 |
| Miller, JP | 1 |
| Dorkenoo, AM | 1 |
| Sodahlon, YK | 1 |
| Bronzan, RN | 1 |
| Yakpa, K | 1 |
| Sossou, E | 1 |
| Ouro-Medeli, A | 1 |
| Teko, M | 1 |
| Seim, A | 1 |
| Mathieu, E | 5 |
| Bulman, CA | 1 |
| Bidlow, CM | 1 |
| Lustigman, S | 1 |
| Cho-Ngwa, F | 1 |
| Williams, D | 1 |
| Rascón, AA | 1 |
| Tricoche, N | 1 |
| Samje, M | 1 |
| Bell, A | 1 |
| Suzuki, B | 1 |
| Lim, KC | 1 |
| Supakorndej, N | 1 |
| Supakorndej, P | 1 |
| Wolfe, AR | 1 |
| Knudsen, GM | 1 |
| Chen, S | 1 |
| Wilson, C | 1 |
| Ang, KH | 1 |
| Arkin, M | 1 |
| Gut, J | 1 |
| Franklin, C | 1 |
| Marcellino, C | 1 |
| McKerrow, JH | 1 |
| Debnath, A | 1 |
| Sakanari, JA | 1 |
| Majewski, AC | 1 |
| Kerketa, AS | 1 |
| Maharana, A | 1 |
| Panda, SS | 1 |
| Mohanty, PC | 1 |
| Kumar, VA | 3 |
| Dembele, B | 2 |
| Konaté, S | 2 |
| Toure, YT | 1 |
| Traore, SF | 3 |
| Arunachalam, N | 5 |
| White, GB | 2 |
| Baea, M | 1 |
| Maki, E | 1 |
| Lombore, B | 1 |
| Fleckenstein, LL | 2 |
| Gonzalez, M | 1 |
| Dadzie, SK | 1 |
| Ahorlu, CK | 1 |
| Appawu, MA | 1 |
| Gyapong, J | 2 |
| Sognikin, E | 1 |
| Akosa, A | 1 |
| Mathieu, EM | 1 |
| Deming, M | 1 |
| Saathof, E | 1 |
| Maboko, L | 1 |
| Makunde, WH | 1 |
| Mviombo, P | 1 |
| Pitter, B | 1 |
| Mgeni, N | 1 |
| Mabuye, J | 1 |
| Kowuor, D | 1 |
| Löscher, T | 1 |
| Vinubala, C | 1 |
| Desormeaux, AM | 1 |
| Monestime, F | 1 |
| Desir, L | 2 |
| Carciunoiu, S | 1 |
| Miller, L | 1 |
| Knipes, A | 1 |
| Lammie, P | 2 |
| Smith, P | 1 |
| Stockton, M | 1 |
| Trofimovich, L | 1 |
| Bhandari, K | 1 |
| Reithinger, R | 1 |
| Ottesen, E | 2 |
| Damayanti, R | 1 |
| Titaley, CR | 1 |
| Suharno, N | 1 |
| Bradley, M | 2 |
| Lynam, T | 1 |
| Chandrasena, NT | 1 |
| Samarasekera, DS | 1 |
| Mupfasoni, D | 1 |
| Montresor, A | 2 |
| Mikhailov, A | 1 |
| King, J | 1 |
| Singh, BK | 1 |
| Wamae, CN | 3 |
| Mwandawiro, CS | 1 |
| Gunawardena, NK | 1 |
| Amarasekera, ND | 1 |
| Pathmeswaran, A | 1 |
| Gunawardena, S | 1 |
| Sri Ranganathan, S | 1 |
| Fernandopulle, R | 1 |
| Chanteau, S | 1 |
| Roux, JF | 1 |
| Sharma, R | 2 |
| Mary, KA | 1 |
| Dhamodharan, R | 2 |
| Massa, K | 1 |
| Magnussen, P | 1 |
| Sheshe, A | 1 |
| Ntakamulenga, R | 1 |
| Ndawi, B | 1 |
| Olsen, A | 2 |
| Kastens, W | 1 |
| Susapu, M | 1 |
| Laney, SJ | 1 |
| Williams, SA | 1 |
| Shenoy, RK | 5 |
| Suma, TK | 3 |
| Kumaraswami, V | 3 |
| Rahmah, N | 1 |
| Dhananjayan, G | 1 |
| Padma, S | 1 |
| Subramaniyan, K | 1 |
| Lipner, EM | 1 |
| Diallo, DA | 2 |
| Yalcouye, D | 1 |
| Doumbo, OK | 2 |
| Traore, AK | 1 |
| Keita, AD | 1 |
| Fay, MP | 2 |
| Hopkins, AD | 1 |
| Gustavsen, KM | 1 |
| Wright, AL | 1 |
| Hooper, PJ | 1 |
| Biswas, G | 3 |
| Ranganath, BG | 1 |
| Gambhir, M | 1 |
| Tisch, D | 1 |
| Kazura, J | 1 |
| Remais, J | 1 |
| Spear, R | 1 |
| Rwegoshora, RT | 1 |
| Sudomo, M | 1 |
| Chayabejara, S | 1 |
| Duong, S | 1 |
| Hernandez, L | 2 |
| Wu, WP | 1 |
| Bergquist, R | 1 |
| Cantey, PT | 1 |
| Rout, J | 1 |
| Rao, G | 1 |
| Williamson, J | 1 |
| Taylor, MJ | 3 |
| Derouiche, A | 1 |
| El Atat, R | 1 |
| Mechri, M | 1 |
| Garbouj, N | 1 |
| Ezzeddine, A | 1 |
| Khaled, A | 1 |
| Chebil, M | 1 |
| Zielinski-Gutierrez, E | 1 |
| Pa'au, M | 1 |
| Ngugi, BM | 1 |
| Mbui, J | 1 |
| Njaanake, HK | 1 |
| Tan, LH | 1 |
| Fong, MY | 1 |
| Mahmud, R | 1 |
| Muslim, A | 1 |
| Lau, YL | 1 |
| Kamarulzaman, A | 1 |
| Namwanje, H | 1 |
| Kabatereine, N | 1 |
| Ramasamy, D | 1 |
| Laxmanappa, HS | 1 |
| Das, MK | 1 |
| Vanamail, P | 1 |
| Yuvaraj, J | 1 |
| Anto, F | 1 |
| Asoala, V | 1 |
| Anyorigiya, T | 1 |
| Oduro, A | 1 |
| Adjuik, M | 1 |
| Akweongo, P | 1 |
| Aborigo, R | 1 |
| Bimi, L | 1 |
| Amankwa, J | 1 |
| Hodgson, A | 1 |
| Mand, S | 1 |
| Specht, S | 1 |
| Ashton, RA | 1 |
| Kyabayinze, DJ | 1 |
| Opio, T | 1 |
| Auma, A | 1 |
| Edwards, T | 1 |
| Matwale, G | 1 |
| Onapa, A | 1 |
| Brooker, S | 1 |
| Kolaczinski, JH | 1 |
| Pam, D | 1 |
| Rakers, LJ | 1 |
| Sambo, Y | 3 |
| Ibrahim, B | 2 |
| Ogah, G | 1 |
| Goshit, D | 1 |
| Oyenekan, OK | 1 |
| Withers, PC | 2 |
| Jiya, J | 2 |
| Hopkins, DR | 1 |
| Goldman, AS | 2 |
| Direny, A | 1 |
| Oscard, R | 1 |
| Vely, JF | 1 |
| Linehan, M | 1 |
| Jip, N | 1 |
| Alphonsus, KM | 1 |
| Graves, P | 1 |
| Turay, H | 1 |
| Maccarthy, F | 1 |
| Gayen, P | 1 |
| Nayak, A | 1 |
| Saini, P | 1 |
| Mukherjee, N | 1 |
| Maitra, S | 1 |
| Sarkar, P | 1 |
| Sinha Babu, SP | 1 |
| Mohammed, KA | 2 |
| Deb, RM | 1 |
| Sharma, DC | 1 |
| Ismid, IS | 1 |
| Rückert, P | 2 |
| John, A | 2 |
| Arun, SR | 1 |
| Na-Bangchang, K | 1 |
| Mani, TR | 7 |
| Satyanarayana, K | 4 |
| Burkot, TR | 1 |
| Taleo, G | 2 |
| Toeaso, V | 1 |
| Ichimori, K | 1 |
| Zagaria, N | 1 |
| McLaughlin, SI | 1 |
| Radday, J | 4 |
| Michel, MC | 1 |
| Beach, MJ | 6 |
| Lammie, J | 1 |
| Rheingans, R | 2 |
| Lafontant, J | 1 |
| van Oortmarssen, GJ | 2 |
| Habbema, JD | 2 |
| Chinbuah, MA | 1 |
| Gyapong, M | 2 |
| Dean, M | 2 |
| Addiss, D | 3 |
| Critchley, J | 3 |
| Ejere, H | 3 |
| Gelband, H | 3 |
| Gamble, C | 3 |
| El Setouhy, M | 2 |
| Ahmed, ES | 3 |
| Kandil, AM | 2 |
| Hussain, O | 1 |
| Farid, HA | 2 |
| Helmy, H | 4 |
| Abdullah, SM | 1 |
| Kirodian, BG | 1 |
| Mehendale, AM | 1 |
| Karbwang, J | 1 |
| Babu, BV | 2 |
| Ramirez, BL | 1 |
| Alberto, FF | 1 |
| Collins, M | 1 |
| Nfonsam, V | 1 |
| Punsalan, T | 1 |
| Kron, MA | 1 |
| Maizels, RM | 1 |
| Dash, AP | 5 |
| Melrose, WD | 2 |
| De Rochars, MB | 3 |
| Roberts, JM | 3 |
| Dardith, D | 1 |
| Lafontant, JG | 2 |
| Hussein, O | 1 |
| Pam, DD | 1 |
| Gerlong, GY | 1 |
| Onyeka, J | 1 |
| Terranella, A | 1 |
| Kumbak, D | 1 |
| Dakul, A | 1 |
| Lenhart, A | 1 |
| Amadiegwu, S | 1 |
| Jinadu, MY | 2 |
| Furness, BW | 1 |
| Haser, JK | 1 |
| Brissau, JM | 1 |
| Louis-Charles, J | 1 |
| Wilson, SF | 1 |
| McCarthy, J | 1 |
| Fraser, M | 1 |
| Taleo, F | 1 |
| Yaviong, J | 1 |
| Amos, M | 1 |
| Babu, M | 1 |
| Kalkoa, M | 1 |
| Sahoo, PK | 1 |
| Satapathy, AK | 1 |
| Ravindran, B | 2 |
| Kanjilal, S | 2 |
| Rheingans, RD | 1 |
| Haddix, AC | 2 |
| Rath, K | 1 |
| Kerketta, AS | 1 |
| Swain, BK | 1 |
| Mishra, S | 1 |
| Ellethy, AS | 1 |
| Setouhy, ME | 1 |
| Padmasiri, EA | 1 |
| de Kraker, ME | 1 |
| Reuben, R | 1 |
| Semnani, RT | 1 |
| Keiser, PB | 1 |
| Keita, F | 1 |
| Traore, D | 1 |
| Malecela-Lazaro, MN | 1 |
| Blackburn, BG | 1 |
| Gotau, H | 1 |
| Gerlong, G | 1 |
| Hawley, WA | 1 |
| Manoempil, P | 1 |
| Servais, G | 1 |
| Gunawardena, GS | 1 |
| Ismail, MM | 3 |
| Karunaweera, ND | 1 |
| Rizzo, JA | 1 |
| Belo, C | 1 |
| Lins, R | 1 |
| Dreyer, G | 2 |
| Grady, CA | 1 |
| Orelus, JN | 1 |
| Wendt, J | 1 |
| Wynd, S | 1 |
| Durrheim, DN | 1 |
| Carron, J | 1 |
| Guisinger, VH | 1 |
| Aikins, M | 1 |
| Amarillo, ML | 1 |
| Belizario, VY | 2 |
| Garshong, B | 1 |
| Kabali, C | 1 |
| Kamal, HA | 2 |
| Lizardo, J | 1 |
| Malecela, M | 1 |
| Mubyazi, G | 1 |
| Nitièma, PA | 1 |
| Wallace, A | 1 |
| Huang, CY | 1 |
| Twum-Danso, NA | 1 |
| Shannon, WD | 1 |
| Haji, HJ | 1 |
| Gabrielli, AF | 1 |
| Mubila, L | 1 |
| Chitsulo, L | 1 |
| Engels, D | 1 |
| Savioli, L | 1 |
| Ogbu Pearce, P | 1 |
| Njepuome, AN | 1 |
| Pfarr, KM | 1 |
| Wibowo, H | 1 |
| Houwing-Duistermaat, JJ | 1 |
| Yazdanbakhsh, M | 1 |
| Sartono, E | 1 |
| Duke, BO | 1 |
| Karam, M | 2 |
| Behbehani, K | 1 |
| Prospere, R | 1 |
| Dalia, S | 1 |
| Cox, FE | 1 |
| Norões, J | 1 |
| Figueredo-Silva, J | 1 |
| Piessens, WF | 1 |
| Witt, C | 1 |
| Lazdins, JK | 1 |
| Awadzi, K | 1 |
| Dunyo, SK | 1 |
| Espinel, M | 1 |
| Hossain, M | 1 |
| Jayakody, RL | 1 |
| Makunde, W | 1 |
| Richard-Lenoble, D | 1 |
| Selve, B | 1 |
| Weerasooriya, MV | 1 |
| Grobusch, MP | 1 |
| Göbels, K | 1 |
| Teichmann, D | 1 |
| Bergmann, F | 1 |
| Suttorp, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis[NCT02899936] | 23,789 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators[NCT03352206] | 20,092 participants (Actual) | Observational | 2017-10-18 | Completed | |||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire][NCT02974049] | 189 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast[NCT02032043] | 14,457 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji[NCT03177993] | 4,773 participants (Actual) | Interventional | 2017-07-13 | Completed | |||
| Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations[NCT03036059] | Phase 4 | 1,462 participants (Actual) | Interventional | 2017-05-19 | Completed | ||
| A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis[NCT04410406] | Phase 3 | 164 participants (Actual) | Interventional | 2020-08-20 | Active, not recruiting | ||
| Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa[NCT01975441] | Phase 2 | 182 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire[NCT02845713] | Phase 1 | 66 participants (Actual) | Interventional | 2016-04-17 | Completed | ||
| AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole[NCT01903057] | Phase 4 | 0 participants (Actual) | Interventional | 2014-02-28 | Withdrawn (stopped due to As of November 2013, the security situation in rural Northern Mozambique is no longer suitable for this clinical trial.) | ||
| A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali[NCT01586169] | 3,000 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to[NCT04124250] | 10,500 participants (Anticipated) | Observational | 2019-09-17 | Recruiting | |||
| Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali[NCT02784743] | Phase 4 | 1,139 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline[NCT00340691] | Phase 2 | 1,500 participants | Interventional | 2004-12-06 | Completed | ||
| Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections[NCT01050517] | 250 participants (Anticipated) | Interventional | 2007-10-31 | Completed | |||
| Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth[NCT00817713] | 295 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.) | |||
| Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study[NCT00339417] | Phase 2 | 1,000 participants (Anticipated) | Interventional | 2006-02-22 | Completed | ||
| Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis[NCT03238131] | Phase 3 | 272 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren[NCT00207753] | 550 participants | Interventional | 2005-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
31 reviews available for albendazole and Bancroftian Elephantiasis
| Article | Year |
|---|---|
Efficacy and safety of triple therapy versus dual therapy for lymphatic filariasis: A systematic review and meta-analysis.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filari | 2022 |
Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review.
Topics: Albendazole; Azithromycin; Drug Therapy, Combination; Elephantiasis, Filarial; Feasibility Studies; | 2023 |
Anti-
Topics: Adult; Albendazole; Animals; Anti-Bacterial Agents; Doxycycline; Drug Therapy, Combination; Elephant | 2019 |
The story of Lymphatic Filariasis elimination as a public health problem from Yemen.
Topics: Albendazole; Animals; Elephantiasis, Filarial; Humans; Ivermectin; Mass Drug Administration; Public | 2020 |
Setting the stage for a Global Programme to Eliminate Lymphatic Filariasis: the first 125 years (1875-2000).
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; Ivermectin | 2020 |
Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
Topics: Albendazole; Animals; Anthelmintics; Elephantiasis, Filarial; Endemic Diseases; Ghana; Humans; Iverm | 2017 |
Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2018 |
Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
Topics: Albendazole; Antigens, Helminth; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filar | 2019 |
Flubendazole as a macrofilaricide: History and background.
Topics: Albendazole; Animals; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Gastrointestinal Dis | 2019 |
EBM verdict: should albendazole be used for treating lymphatic filariasis? No.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; Social Problems | 2019 |
Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
Topics: Albendazole; Anthelmintics; Chemoprevention; Diethylcarbamazine; Disease Eradication; Elephantiasis, | 2013 |
The development of albendazole for lymphatic filariasis.
Topics: Albendazole; Animals; Drug Administration Schedule; Drug Therapy, Combination; Elephantiasis, Filari | 2009 |
The development of albendazole for lymphatic filariasis.
Topics: Albendazole; Animals; Drug Administration Schedule; Drug Therapy, Combination; Elephantiasis, Filari | 2009 |
The development of albendazole for lymphatic filariasis.
Topics: Albendazole; Animals; Drug Administration Schedule; Drug Therapy, Combination; Elephantiasis, Filari | 2009 |
The development of albendazole for lymphatic filariasis.
Topics: Albendazole; Animals; Drug Administration Schedule; Drug Therapy, Combination; Elephantiasis, Filari | 2009 |
Elimination of lymphatic filariasis in Southeast Asia.
Topics: Albendazole; Animals; Asia, Southeastern; Brugia; China; Diethylcarbamazine; Elephantiasis, Filarial | 2010 |
Lymphatic filariasis and onchocerciasis.
Topics: Africa South of the Sahara; Age Factors; Albendazole; Animals; Anti-Bacterial Agents; Antinematodal | 2010 |
Filariasis in Africa--treatment challenges and prospects.
Topics: Africa; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Humans; Ivermectin; Onchocerca v | 2011 |
Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.
Topics: Albendazole; Animals; Anthelmintics; Brugia; Child; Elephantiasis, Filarial; Female; Humans; Ivermec | 2011 |
Lymphatic filariasis elimination: progress in global programme development.
Topics: Albendazole; Developing Countries; Disability Evaluation; Elephantiasis, Filarial; Filaricides; Fina | 2002 |
Mass drug treatment for lymphatic filariasis and onchocerciasis.
Topics: Africa; Albendazole; Animals; Drug Evaluation, Preclinical; Drug Resistance; Elephantiasis, Filarial | 2003 |
Albendazole for lymphatic filariasis.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; Ivermectin; Randomize | 2004 |
Lymphatic filariasis and Brugia timori: prospects for elimination.
Topics: Albendazole; Animals; Brugia; Diethylcarbamazine; Elephantiasis, Filarial; Female; Filaricides; Huma | 2004 |
Chemotherapy for lymphatic filariasis: progress but not perfection.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Humans | 2003 |
Albendazole for the control and elimination of lymphatic filariasis: systematic review.
Topics: Adult; Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filarici | 2005 |
Albendazole for lymphatic filariasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2005 |
Controlling lymphatic filariasis and soil-transmitted helminthiasis together in South Asia: opportunities and challenges.
Topics: Albendazole; Anthelmintics; Ascariasis; Asia; Elephantiasis, Filarial; Endemic Diseases; Helminthias | 2006 |
Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Child; Diethylca | 2006 |
Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.
Topics: Albendazole; Community Health Services; Cultural Characteristics; Diethylcarbamazine; Drug Therapy, | 2007 |
Strategies and tools for the control/elimination of lymphatic filariasis.
Topics: Adult; Africa; Albendazole; Animals; Anthelmintics; Asia; Child; Diethylcarbamazine; Drug Administra | 1997 |
Strategies and tools for the control/elimination of lymphatic filariasis.
Topics: Adult; Africa; Albendazole; Animals; Anthelmintics; Asia; Child; Diethylcarbamazine; Drug Administra | 1997 |
Strategies and tools for the control/elimination of lymphatic filariasis.
Topics: Adult; Africa; Albendazole; Animals; Anthelmintics; Asia; Child; Diethylcarbamazine; Drug Administra | 1997 |
Strategies and tools for the control/elimination of lymphatic filariasis.
Topics: Adult; Africa; Albendazole; Animals; Anthelmintics; Asia; Child; Diethylcarbamazine; Drug Administra | 1997 |
The role of albendazole in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Human | 1999 |
Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective.
Topics: Albendazole; Animals; Anthelmintics; Diethylcarbamazine; Elephantiasis, Filarial; Female; Filaricide | 2000 |
[The control of lymphatic filariasis].
Topics: Albendazole; Animals; Anthelmintics; Brugia; Brugia malayi; Disease Vectors; Elephantiasis, Filarial | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
Topics: Albendazole; Clinical Trials as Topic; Diethylcarbamazine; Drug Synergism; Drug Therapy, Combination | 2000 |
40 trials available for albendazole and Bancroftian Elephantiasis
| Article | Year |
|---|---|
Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Child; Child, Preschool; Diethylcarbamazine; Drug The | 2022 |
Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia.
Topics: Albendazole; Animals; Cross-Sectional Studies; Elephantiasis, Filarial; Helminthiasis; Humans; Iverm | 2022 |
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Topics: Albendazole; Cross-Sectional Studies; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, | 2022 |
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Topics: Albendazole; Cross-Sectional Studies; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, | 2022 |
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Topics: Albendazole; Cross-Sectional Studies; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, | 2022 |
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Topics: Albendazole; Cross-Sectional Studies; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, | 2022 |
A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Female; Filaric | 2023 |
Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study.
Topics: Adult; Albendazole; Animals; Cote d'Ivoire; Diethylcarbamazine; Drug Therapy, Combination; Elephanti | 2023 |
Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis.
Topics: Adolescent; Adult; Aged; Albendazole; Antigens, Helminth; Cytokines; Diethylcarbamazine; Elephantias | 2019 |
Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.
Topics: Albendazole; Animals; Cote d'Ivoire; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, F | 2020 |
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Antiparasitic Agents; Child; Child, Prescho | 2020 |
Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
Topics: Adolescent; Adult; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Diethylcarba | 2020 |
Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
Topics: Albendazole; Animals; Diethylcarbamazine; Elephantiasis, Filarial; Female; Filaricides; Humans; Iver | 2021 |
An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Diethylcarbamazine; Drug-Related Side Effects and Ad | 2021 |
A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
Topics: Adolescent; Adult; Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Female; Filaricides; Fo | 2021 |
Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire.
Topics: Albendazole; Animals; Cote d'Ivoire; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Iverm | 2022 |
Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
Topics: Albendazole; Animals; Australia; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filar | 2021 |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antibodies, Protozoan; Asymptomatic Diseases; Brugia; | 2021 |
Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
Topics: Adult; Albendazole; Animals; Antigens, Helminth; Diethylcarbamazine; Double-Blind Method; Drug Admin | 2017 |
Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
Topics: Albendazole; Animals; Clinical Protocols; Community Health Services; Culicidae; Disease Eradication; | 2017 |
Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.
Topics: Administration, Oral; Adolescent; Albendazole; Animals; Asymptomatic Infections; Child; Child, Presc | 2017 |
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
Topics: Adolescent; Adult; Albendazole; Animals; Diethylcarbamazine; Drug Administration Schedule; Drug Ther | 2018 |
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
Topics: Adolescent; Adult; Albendazole; Animals; Diethylcarbamazine; Drug Administration Schedule; Drug Ther | 2018 |
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
Topics: Adolescent; Adult; Albendazole; Animals; Diethylcarbamazine; Drug Administration Schedule; Drug Ther | 2018 |
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
Topics: Adolescent; Adult; Albendazole; Animals; Diethylcarbamazine; Drug Administration Schedule; Drug Ther | 2018 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cohort Studies; Cote d'Ivoire; Diethylcarbamazine; Dr | 2019 |
A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Anti-Bacterial Agents; Azithromycin; Chemopreve | 2013 |
A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Anti-Bacterial Agents; Azithromycin; Chemopreve | 2013 |
A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Anti-Bacterial Agents; Azithromycin; Chemopreve | 2013 |
A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Anti-Bacterial Agents; Azithromycin; Chemopreve | 2013 |
A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Dose-Response Relationship, Drug; Drug Therapy, Com | 2015 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
A randomized trial of doxycycline for Mansonella perstans infection.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anti-Bacterial Agents; Doxycycline; Drug Therapy, Com | 2009 |
Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Ch | 2011 |
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda.
Topics: Adolescent; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Cost-Benefit Analys | 2011 |
A double-blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Anti-Bacterial Agents; Bacterial Load; | 2013 |
Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.
Topics: Adolescent; Adult; Albendazole; Animals; Brugia; Diethylcarbamazine; Drug Therapy, Combination; Elep | 2002 |
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
Topics: Administration, Oral; Adolescent; Adult; Albendazole; Chromatography, Gas; Chromatography, High Pres | 2002 |
A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Dose-Response Relationship, Drug; Drug Administrati | 2004 |
Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Child; Child, Preschool; Diethylcarbamazine | 2004 |
Duplex Doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in Bancroftian filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; | 2004 |
Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.
Topics: Adolescent; Adult; Albendazole; Animals; Ascariasis; Ascaris; Elephantiasis, Filarial; Female; Filar | 2005 |
Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Female | 2006 |
Filaria-induced monocyte dysfunction and its reversal following treatment.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Drug Therapy, Combination; Elephantiasis, | 2006 |
Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Brazil; Child; Diethylcarbamazine; Drug Ther | 2007 |
Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Child, Preschool; Drug Therapy, Combination; E | 2008 |
Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Child; Diethylcarbamazine; Double-Blin | 2008 |
Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren.
Topics: Albendazole; Animals; Anthelmintics; Ascariasis; Body Height; Child; Child, Preschool; Double-Blind | 1999 |
Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren.
Topics: Albendazole; Animals; Anthelmintics; Ascariasis; Body Height; Child; Child, Preschool; Double-Blind | 1999 |
Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren.
Topics: Albendazole; Animals; Anthelmintics; Ascariasis; Body Height; Child; Child, Preschool; Double-Blind | 1999 |
Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren.
Topics: Albendazole; Animals; Anthelmintics; Ascariasis; Body Height; Child; Child, Preschool; Double-Blind | 1999 |
Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Drug Administratio | 1999 |
195 other studies available for albendazole and Bancroftian Elephantiasis
| Article | Year |
|---|---|
Assessing factors influencing communities' acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana.
Topics: Albendazole; Community Health Services; Cross-Sectional Studies; Data Collection; Diethylcarbamazine | 2021 |
Soil-transmitted helminth infections after mass drug administration for lymphatic filariasis in rural southern India.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Cross-Section | 2022 |
Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Antigens, Helminth; Child; Child, Preschool | 2021 |
Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment.
Topics: Adolescent; Adult; Albendazole; Antigens, Helminth; Child; Congo; Elephantiasis, Filarial; Female; F | 2021 |
Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antigens, Helminth; Cross-Sectional Studies; Disease | 2022 |
Efficacy and safety of triple therapy versus dual therapy for lymphatic filariasis: Discordance between conclusion and findings.
Topics: Albendazole; Elephantiasis, Filarial; Filaricides; Humans | 2022 |
Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin-Diethylcarbamazine-Albendazole for Lymphatic Filariasis Elimination.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Encephalitis, Japanese; Filaricides; Human | 2022 |
Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2022 |
The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2022 |
Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; India; Ivermectin | 2022 |
Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2022 |
Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2022 |
Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; He | 2022 |
Filariasis presenting as pancytopenia in a child.
Topics: Albendazole; Animals; Child; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; | 2022 |
Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria.
Topics: Albendazole; Child; Child, Preschool; Elephantiasis, Filarial; Humans; Ivermectin; Nigeria; Onchocer | 2022 |
Lymphatic filarial serum proteome profiling for identification and characterization of diagnostic biomarkers.
Topics: Albendazole; Biomarkers; Elephantiasis, Filarial; Humans; Proteome; Spectroscopy, Fourier Transform | 2022 |
Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
Topics: Albendazole; American Samoa; Animals; Child; Diethylcarbamazine; Elephantiasis, Filarial; Filaricide | 2022 |
Step towards elimination of Wuchereria bancrofti in Southwest Tanzania 10 years after mass drug administration with Albendazole and Ivermectin.
Topics: Albendazole; Animals; Antigens, Helminth; Elephantiasis, Filarial; Filaricides; Follow-Up Studies; H | 2022 |
No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds.
Topics: Albendazole; Animals; Cross-Sectional Studies; Elephantiasis, Filarial; Filaricides; Humans; Immunog | 2022 |
Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana.
Topics: Albendazole; Drug-Related Side Effects and Adverse Reactions; Elephantiasis, Filarial; Female; Ghana | 2022 |
Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; India; Iodine; Sodium | 2022 |
Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Topics: Africa; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Ivermectin; Prevalence; Wucherer | 2022 |
Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Topics: Africa; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Ivermectin; Prevalence; Wucherer | 2022 |
Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Topics: Africa; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Ivermectin; Prevalence; Wucherer | 2022 |
Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa.
Topics: Africa; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Ivermectin; Prevalence; Wucherer | 2022 |
[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].
Topics: Adolescent; Albendazole; Burkina Faso; Elephantiasis, Filarial; Female; Humans; Ivermectin; Male; Ma | 2022 |
Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa.
Topics: Albendazole; American Samoa; Animals; Elephantiasis, Filarial; Filaricides; Humans; Mass Drug Admini | 2023 |
Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis.
Topics: Albendazole; Animals; Elephantiasis, Filarial; Female; Filaricides; Ivermectin; Mass Drug Administra | 2023 |
IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis.
Topics: Albendazole; Animals; Antibodies, Helminth; Antigens, Helminth; Diethylcarbamazine; Elephantiasis, F | 2023 |
Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Female; Humans; | 2023 |
Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Female; Humans; Ivermectin; Macrolides; Ma | 2023 |
Integrated Prevalence Assessment of Wuchereria bancrofti and Onchocerca volvulus in Three Co-Endemic Districts of Gambella Region, Ethiopia.
Topics: Albendazole; Animals; Antigens, Helminth; Child; Elephantiasis, Filarial; Ethiopia; Female; Humans; | 2023 |
Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
Topics: Albendazole; Animals; Child; Child, Preschool; Disease Eradication; Elephantiasis, Filarial; Endemic | 2019 |
The division of labour between community medicine distributors influences the reach of mass drug administration: A cross-sectional study in rural Uganda.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Community Hea | 2019 |
Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis.
Topics: Albendazole; Animals; Antigens, Helminth; Brugia malayi; Drug Therapy, Combination; Elephantiasis, F | 2019 |
Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis.
Topics: Albendazole; Animals; Delayed-Action Preparations; Diethylcarbamazine; Doxycycline; Drug Carriers; D | 2019 |
Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elepha | 2020 |
Are census data accurate for estimating coverage of a lymphatic filariasis MDA campaign? Results of a survey in Sierra Leone.
Topics: Adult; Albendazole; Censuses; Chemoprevention; Elephantiasis, Filarial; Female; Filaricides; Helmint | 2019 |
Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Child; Child, Preschool; Cross-Sec | 2020 |
Elimination of diurnally sub-periodic Wuchereria bancrofti in Andaman and Nicobar Islands, India, using mass DEC-fortified salt as a supplementary intervention to MDA.
Topics: Albendazole; Animals; Antigens, Helminth; Child; Child, Preschool; Dietary Supplements; Diethylcarba | 2020 |
Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys.
Topics: Albendazole; Anthelmintics; Child; Child, Preschool; Elephantiasis, Filarial; Female; Filaricides; H | 2020 |
Single-Dose Triple-Drug Therapy for
Topics: Albendazole; Animals; Antigens, Helminth; Diethylcarbamazine; Drug Therapy, Combination; Elephantias | 2020 |
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis.
Topics: Albendazole; Diethylcarbamazine; Disease Transmission, Infectious; Elephantiasis, Filarial; Filarici | 2020 |
The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antigens, Helminth; Ascariasis; Ascaris lumb | 2020 |
Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence.
Topics: Albendazole; Animals; Antigens, Helminth; Cohort Studies; Congo; Diethylcarbamazine; Elephantiasis, | 2021 |
Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d'Ivoire.
Topics: Adolescent; Adult; Albendazole; Ancylostomatoidea; Animals; Child; Cote d'Ivoire; Cross-Sectional St | 2020 |
A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Female | 2020 |
A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filaricides; Hu | 2020 |
Achievements and challenges of lymphatic filariasis elimination in Sierra Leone.
Topics: Albendazole; Animals; Brugia malayi; Child; Child, Preschool; Disease Eradication; Elephantiasis, Fi | 2020 |
Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Brugia malayi; Diethylcarbamazine; Ele | 2020 |
Effect of Lymphatic Filariasis and Hookworm Infection on Pregnancy Course and Outcome in Women Living in the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Antigens, Helminth; Democratic Republic of the | 2021 |
A strong effect of individual compliance with mass drug administration for lymphatic filariasis on sustained clearance of soil-transmitted helminth infections.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Democratic Republic | 2021 |
Lymphatic filariasis elimination in the Dominican Republic: History, progress, and remaining steps.
Topics: Albendazole; Diethylcarbamazine; Disease Eradication; Dominican Republic; Elephantiasis, Filarial; H | 2021 |
Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India.
Topics: Albendazole; Animals; Diethylcarbamazine; Disease Eradication; Drug Therapy, Combination; Elephantia | 2017 |
Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Child; Elephantiasis, | 2017 |
Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets
Topics: Albendazole; Animals; Child; Cross-Sectional Studies; Diethylcarbamazine; Disease Eradication; Eleph | 2017 |
First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
Topics: Albendazole; Animals; Antigens, Helminth; Cameroon; Child; Child, Preschool; Chromatography, Affinit | 2017 |
Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
Topics: Albendazole; Child; Diethylcarbamazine; Disease Transmission, Infectious; Drug Therapy; Drug Utiliza | 2017 |
Criteria to Stop Mass Drug Administration for Lymphatic Filariasis Have Been Achieved Throughout Plateau and Nasarawa States, Nigeria.
Topics: Albendazole; Anthelmintics; Antigens, Helminth; Child; Chromatography, Affinity; Elephantiasis, Fila | 2017 |
An evaluation of Wb123 antibody elisa in individuals treated with ivermectin and albendazole, and implementation challenges in Africa.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Antibo | 2017 |
Twelve-month longitudinal parasitological assessment of lymphatic filariasis-positive individuals: impact of a biannual treatment with ivermectin and albendazole.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antigens, Helminth; Child; Elephantiasis, Filarial; F | 2017 |
Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration.
Topics: Adolescent; Adult; Aedes; Albendazole; American Samoa; Animals; Antibodies, Helminth; Antigens, Helm | 2017 |
Global programme to eliminate lymphatic filariasis: progress report, 2016.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Disease Eradication; Drug Therapy, Combination; Elep | 2017 |
Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Child; Diethylcarbamazine; Elephantiasis, Filarial; F | 2017 |
The interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated chemotherapy in the Obongi focus, North Western Uganda.
Topics: Adolescent; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Elephantiasis, Fila | 2017 |
Human infection with sub-periodic Brugia spp. in Gampaha District, Sri Lanka: a threat to filariasis elimination status?
Topics: Adolescent; Adult; Age Factors; Albendazole; Animals; Brugia; Child; Child, Preschool; Communicable | 2018 |
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Topics: Africa South of the Sahara; Albendazole; Animals; Diethylcarbamazine; Drug Synergism; Drug Therapy, | 2018 |
How elimination of lymphatic filariasis as a public health problem in the Kingdom of Cambodia was achieved.
Topics: Adult; Albendazole; Cambodia; Child; Diethylcarbamazine; Elephantiasis, Filarial; Health Personnel; | 2018 |
Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa.
Topics: Albendazole; American Samoa; Animals; Antibodies, Helminth; Antigens, Helminth; Child; Child, Presch | 2018 |
Status of lymphatic filariasis with progression of age and gender & eradication strategies: A survey among residents of Hardoi district of Uttar Pradesh, an endemic region of North India.
Topics: Adolescent; Adult; Age Factors; Aged; Albendazole; Animals; Anopheles; Antiparasitic Agents; Brugia | 2018 |
Lymphatic filariasis elimination programme in Assam, India, needs change in mass drug administration strategy to target the focus of infection.
Topics: Albendazole; Animals; Diethylcarbamazine; Elephantiasis, Filarial; Female; Filaricides; Humans; Indi | 2018 |
Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
Topics: Albendazole; Animals; Computer Simulation; Diethylcarbamazine; Disease Eradication; Drug Therapy, Co | 2018 |
Progress on elimination of lymphatic filariasis in Sierra Leone.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Disease Eradication; Elephantiasis, Filarial; Female | 2018 |
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Child; Disease Eradication; Drug Administra | 2018 |
Comprehensive Assessment of a Hotspot with Persistent Bancroftian Filariasis in Coastal Sri Lanka.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Child; Culex; Di | 2018 |
Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Child; Child, Preschool; Diethylcarbamazine | 2018 |
The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Child; Child, Preschool; Cross-Sec | 2018 |
Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antiprotozoal Agents; Child; Culex; Elephantiasis, Fi | 2018 |
Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
Topics: Albendazole; Animals; Anopheles; Antigens, Helminth; Brugia malayi; Child; Child, Preschool; Cross-S | 2019 |
Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
Topics: Adult; Albendazole; Anthelmintics; Cross-Sectional Studies; Disease Eradication; Disease Susceptibil | 2020 |
Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Diethylcarbamazine; Elephantiasis, | 2019 |
Wuchereria bancrofti-infected individuals harbor distinct IL-10-producing regulatory B and T cell subsets which are affected by anti-filarial treatment.
Topics: Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; B-Lymphocytes, Regulatory; Elep | 2019 |
How Thailand eliminated lymphatic filariasis as a public health problem.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Ca | 2019 |
Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas.
Topics: Albendazole; Animals; Antigens, Helminth; Benin; Child; Disease Eradication; Elephantiasis, Filarial | 2019 |
You're the flight surgeon: lymphatic filariasis.
Topics: Adult; Albendazole; Anthelmintics; Cote d'Ivoire; Elephantiasis, Filarial; Endemic Diseases; Humans; | 2013 |
Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
Topics: Albendazole; Animals; Community Health Services; Community Health Workers; Community Participation; | 2013 |
Lymphatic filariasis elimination programme in Andaman and Nicobar Islands, India: drug coverage and compliance post eight rounds of MDA.
Topics: Adult; Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Humans; India; Medication Adheren | 2013 |
Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.
Topics: Albendazole; Animals; Anthelmintics; Antigens, Helminth; Brugia malayi; Cost-Benefit Analysis; Diagn | 2013 |
Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Diethylcarbamazine; Egypt; Elephan | 2013 |
Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.
Topics: Adolescent; Albendazole; Animals; Child; Child, Preschool; Culicidae; Elephantiasis, Filarial; Filar | 2013 |
Semiparametric regression analysis of clustered interval-censored failure time data with informative cluster size.
Topics: Adolescent; Adult; Aged; Albendazole; Biometry; Cluster Analysis; Computer Simulation; Diethylcarbam | 2013 |
Long-lasting insecticidal nets are synergistic with mass drug administration for interruption of lymphatic filariasis transmission in Nigeria.
Topics: Albendazole; Animals; Anopheles; Communicable Disease Control; Elephantiasis, Filarial; Filaricides; | 2013 |
A longitudinal analysis of the effect of mass drug administration on acute inflammatory episodes and disease progression in lymphedema patients in Leogane, Haiti.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Child; Diethylcarbamazine; Elephantiasis, Filar | 2014 |
Baseline drivers of lymphatic filariasis in Burkina Faso.
Topics: Agriculture; Albendazole; Anthelmintics; Burkina Faso; Climate; Elephantiasis, Filarial; Female; Hum | 2013 |
Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations.
Topics: Albendazole; Animals; Antigens, Helminth; Child; Child, Preschool; Diethylcarbamazine; Drug Administ | 2014 |
Meeting of the International Task Force for Disease Eradication, January 2014.
Topics: Advisory Committees; Africa; Albendazole; Anthelmintics; Disease Eradication; Elephantiasis, Filaria | 2014 |
Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies.
Topics: Albendazole; Chromatography, Liquid; Diethylcarbamazine; Elephantiasis, Filarial; Humans; Ivermectin | 2014 |
Measuring impact on filarial infection status in a community study: role of coverage of mass drug administration (MDA).
Topics: Albendazole; Diethylcarbamazine; Drug Therapy; Drug Utilization; Elephantiasis, Filarial; Filaricide | 2014 |
Decline in lymphatic filariasis transmission with annual mass drug administration using DEC with and without albendazole over a 10year period in India.
Topics: Albendazole; Animals; Culex; Diethylcarbamazine; Disease Eradication; Drug Administration Schedule; | 2015 |
Shrinking the lymphatic filariasis map: update on diagnostic tools for mapping and transmission monitoring.
Topics: Africa; Albendazole; Animals; Antibodies, Helminth; Chromatography, Affinity; Diagnostic Tests, Rout | 2014 |
Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision.
Topics: Adult; Albendazole; Animals; Anthelmintics; Antibodies; Antiparasitic Agents; Child; Child, Preschoo | 2014 |
Factors influencing drug uptake during mass drug administration for control of lymphatic filariasis in rural and urban Tanzania.
Topics: Adolescent; Adult; Albendazole; Child; Child, Preschool; Cross-Sectional Studies; Elephantiasis, Fil | 2014 |
A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Ch | 2014 |
[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
Topics: Albendazole; Animals; Anthelmintics; Antigens, Helminth; Child; Chromatography, Affinity; Cross-Sect | 2015 |
Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Auranofin; Brugia malayi; Cattle; Cell Line; Diethylcarb | 2015 |
The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Antigens, Helminth; | 2015 |
Impact on prevalence of intestinal helminth infection in school children administered with seven annual rounds of diethyl carbamazine (DEC) with albendazole.
Topics: Albendazole; Animals; Child; Diethylcarbamazine; Drug Administration Schedule; Elephantiasis, Filari | 2015 |
The Impact of Six Annual Rounds of Mass Drug Administration on Wuchereria bancrofti Infections in Humans and in Mosquitoes in Mali.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Child, Preschool; Cross-Sectional Studies; Culicidae | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Disease Eradication; Elephantiasi | 2015 |
Residual microfilaraemia in rural pockets of South India after five rounds of DEC plus albendazole administration as part of the LF elimination campaign.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Diethylcarbamazine; | 2015 |
Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic.
Topics: Albendazole; Child; Child, Preschool; Chromatography, Affinity; Diethylcarbamazine; Disease Eradicat | 2015 |
Transmission indices and microfilariae prevalence in human population prior to mass drug administration with ivermectin and albendazole in the Gomoa District of Ghana.
Topics: Albendazole; Animals; Anopheles; Communicable Disease Control; Disease Transmission, Infectious; Ele | 2015 |
Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
Topics: Adolescent; Adult; Albendazole; Antiparasitic Agents; Child; Elephantiasis, Filarial; Female; Helmin | 2016 |
Can community-based integrated vector control hasten the process of LF elimination?
Topics: Albendazole; Animals; Brugia malayi; Community Participation; Culicidae; Diethylcarbamazine; Disease | 2016 |
Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
Topics: Albendazole; Animals; Antigens, Protozoan; Coinfection; Elephantiasis, Filarial; Filaricides; HIV In | 2016 |
Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Topics: Albendazole; Animals; Computer Simulation; Culex; Diethylcarbamazine; Drug Administration Schedule; | 2016 |
Controlling Neglected Tropical Diseases (NTDs) in Haiti: Implementation Strategies and Evidence of Their Success.
Topics: Albendazole; Animals; Anthelmintics; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Haiti | 2016 |
Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
Topics: Adolescent; Adult; Albendazole; Animals; Disease Eradication; Drug Administration Schedule; Elephant | 2016 |
Surveillance for transmission of lymphatic filariasis in Colombo and Gampaha districts of Sri Lanka following mass drug administration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Child; Child, Presc | 2016 |
The Impact of Lymphatic Filariasis Mass Drug Administration Scaling Down on Soil-Transmitted Helminth Control in School-Age Children. Present Situation and Expected Impact from 2016 to 2020.
Topics: Africa; Albendazole; Animals; Anthelmintics; Antinematodal Agents; Asia; Child; Diethylcarbamazine; | 2016 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Topics: Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Diethylcarbamazine; Drug Administration S | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Topics: Africa; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Fi | 2017 |
Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on Wuchereria bancrofti infection and the sensitivity of immunochromatographic test in Malindi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anti-Infective Agents; Antigens, B | 2008 |
Effect of repeated mass chemotherapy for filariasis control on soil-transmitted helminth infections in Sri Lanka.
Topics: Albendazole; Animals; Anthelmintics; Child; Communicable Disease Control; Diethylcarbamazine; Drug T | 2008 |
Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Albendazole; An | 2008 |
[ Bancroftian lymphatic filariasis: toward its elimination from the Pacific?].
Topics: Aedes; Albendazole; Animals; Antigens, Helminth; Diethylcarbamazine; Elephantiasis, Filarial; Filari | 2008 |
A method for detecting microfilaraemia, filarial specific antigens and antibodies and typing of parasites for drug resistance and genotypes using finger prick blood sample.
Topics: Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Blood; DNA Fingerprin | 2008 |
The combined effect of the Lymphatic Filariasis Elimination Programme and the Schistosomiasis and Soil-transmitted Helminthiasis Control Programme on soil-transmitted helminthiasis in schoolchildren in Tanzania.
Topics: Albendazole; Animals; Anthelmintics; Child; Drug Therapy, Combination; Elephantiasis, Filarial; Fema | 2009 |
Lymphatic filariasis elimination programme in India: progress and challenges.
Topics: Albendazole; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; Humans; India; National Healt | 2009 |
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
Topics: Adult; Aging; Albendazole; Animals; Anopheles; Anthelmintics; Antigens, Helminth; Child; Culicidae; | 2008 |
10 years of success in addressing lymphatic filariasis.
Topics: Albendazole; Anthelmintics; Elephantiasis, Filarial; Global Health; Humans; Ivermectin; Time Factors | 2009 |
Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection.
Topics: Adolescent; Albendazole; Animals; Brugia malayi; Child; Child, Preschool; Diethylcarbamazine; Drug C | 2009 |
An allele specific PCR assay for screening for drug resistance among Wuchereria bancrofti populations in India.
Topics: Albendazole; Alleles; Amino Acid Sequence; Animals; Base Sequence; Drug Resistance; Elephantiasis, F | 2009 |
A decade of ivermectin-albendazole donation for lymphatic filariasis.
Topics: Albendazole; Animals; Elephantiasis, Filarial; Endemic Diseases; Global Health; Humans; Ivermectin | 2009 |
GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
Topics: Albendazole; Drug Industry; Elephantiasis, Filarial; Filaricides; Global Health; Humans; Ivermectin; | 2009 |
The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
Topics: Albendazole; Animals; Child; Communicable Disease Control; Disease Progression; Elephantiasis, Filar | 2009 |
Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India.
Topics: Administration, Oral; Adolescent; Adult; Aged; Albendazole; Animals; Child; Child, Preschool; Diethy | 2010 |
Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis.
Topics: Albendazole; Animals; Anthelmintics; Bayes Theorem; Computer Simulation; Diethylcarbamazine; Elephan | 2010 |
Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission.
Topics: Adolescent; Adult; Albendazole; Animals; Antigens, Helminth; Antiparasitic Agents; Child; Child, Pre | 2010 |
Role of community empowerment in the elimination of lymphatic filariasis in south India.
Topics: Albendazole; Anthelmintics; Community Health Services; Community Participation; Diethylcarbamazine; | 2010 |
Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Analysis of Variance; Animals; Child; Child | 2010 |
Post-kidney transplantation lymphocele due to a lymphatic filariasis.
Topics: Albendazole; Antiparasitic Agents; Doxycycline; Drainage; Elephantiasis, Filarial; Humans; Ivermecti | 2010 |
Improving community participation to eliminate lymphatic filariasis in American Samoa.
Topics: Albendazole; American Samoa; Animals; Anthelmintics; Community Participation; Diethylcarbamazine; Dr | 2011 |
Zoonotic Brugia pahangi filariasis in a suburbia of Kuala Lumpur City, Malaysia.
Topics: Adult; Aged; Albendazole; Animals; Cats; Culicidae; Diethylcarbamazine; Elephantiasis, Filarial; Fem | 2011 |
Influence of anti-filarial chemotherapy strategies on the genetic structure of Wuchereria bancrofti populations.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Administration Schedule; Drug Therapy, Combination; E | 2011 |
Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
Topics: Albendazole; Animals; Antigens, Helminth; Culex; Diethylcarbamazine; Drug Administration Schedule; E | 2011 |
Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
Topics: Adolescent; Albendazole; Child; Drug Therapy, Combination; Elephantiasis, Filarial; Endemic Diseases | 2011 |
The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda.
Topics: Adolescent; Albendazole; Animals; Anopheles; Anthelmintics; Child; Child, Preschool; Elephantiasis, | 2011 |
Progress toward elimination of lymphatic filariasis--Togo, 2000--2009.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Chroma | 2011 |
Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Antigens, Helminth; Child; Child, | 2011 |
Costs of integrated mass drug administration for neglected tropical diseases in Haiti.
Topics: Albendazole; Anthelmintics; Costs and Cost Analysis; Diethylcarbamazine; Drug Therapy; Elephantiasis | 2011 |
Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Pres | 2012 |
Maintaining effective mass drug administration for lymphatic filariasis through in-process monitoring in Sierra Leone.
Topics: Albendazole; Animals; Drug Utilization; Elephantiasis, Filarial; Female; Filaricides; Humans; Iverme | 2012 |
Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement.
Topics: Albendazole; Elephantiasis, Filarial; Endemic Diseases; Filaricides; Global Health; Humans; Ivermect | 2012 |
Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis--a rapid assessment methodology to assess impact.
Topics: Adolescent; Adult; Albendazole; Animals; Antiparasitic Agents; Child; Child, Preschool; Drug Therapy | 2012 |
New goals set for filariasis elimination in India.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; | 2002 |
Targeting of children in filariasis mass drug administration.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Child, Preschool; Diethylcarbamazine; Elephant | 2002 |
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.
Topics: Albendazole; Animals; Culicidae; Diethylcarbamazine; Disease Vectors; Elephantiasis, Filarial; Endem | 2002 |
Lymphatic filariasis.
Topics: Albendazole; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Endemic Disease | 2003 |
Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
Topics: Adolescent; Adult; Age Factors; Albendazole; Anthelmintics; Diethylcarbamazine; Elephantiasis, Filar | 2003 |
Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
Topics: Adverse Drug Reaction Reporting Systems; Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Com | 2003 |
Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study.
Topics: Albendazole; Animals; Computer Simulation; Diethylcarbamazine; Elephantiasis, Filarial; Filaricides; | 2003 |
Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Albendazole; Child Developmen | 2003 |
Pacific nations lead the way in fighting lymphatic filariasis. Region aims to eliminate.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Elephantiasis, Filarial; Fiji; Filaricides; Humans; | 2003 |
Impact of two annual single-dose mass drug administrations with diethylcarbamazine alone or in combination with albendazole on Wuchereria bancrofti microfilaraemia and antigenaemia in south India.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Preschool; | 2004 |
Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
Topics: Adolescent; Albendazole; Antiprotozoal Agents; Child; Child, Preschool; Diethylcarbamazine; Drug The | 2004 |
Contrasting Wuchereria bancrofti microfilaria rates in two Mangyan-populated Philippine villages.
Topics: Albendazole; Animals; Antiprotozoal Agents; Child; Child, Preschool; Diethylcarbamazine; Elephantias | 2004 |
Effectiveness of two annual, single-dose mass drug administrations of diethylcarbamazine alone or in combination with albendazole on soil-transmitted helminthiasis in filariasis elimination programme.
Topics: Albendazole; Anthelmintics; Child; Cross-Sectional Studies; Diethylcarbamazine; Drug Therapy, Combin | 2004 |
Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
Topics: Adolescent; Adult; Age Distribution; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; D | 2004 |
Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis.
Topics: Albendazole; Developing Countries; Diethylcarbamazine; Disease Outbreaks; Drug Therapy, Combination; | 2004 |
Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria.
Topics: Albendazole; Animals; Anopheles; Anthelmintics; Culex; Culicidae; Drug Therapy, Combination; Elephan | 2005 |
Ultrasonographic examination of Haitian children with lymphatic filariasis: a longitudinal assessment in the context of antifilarial drug treatment.
Topics: Adolescent; Albendazole; Child; Child, Preschool; Diethylcarbamazine; Elephantiasis, Filarial; Femal | 2005 |
Global programme to eliminate lymphatic filariasis.
Topics: Albendazole; Anthelmintics; Developing Countries; Drug Therapy, Combination; Elephantiasis, Filarial | 2005 |
Is anthelmintic resistance a threat to the program to eliminate lymphatic filariasis?
Topics: Albendazole; Animals; Anthelmintics; Diethylcarbamazine; Drug Resistance; Drug Therapy, Combination; | 2005 |
Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Antigens, Helminth; Bedding and Linens; Child; Child, | 2005 |
The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filari | 2005 |
Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Child, Preschool; Communicable Disease Control; Diet | 2006 |
Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Di | 2006 |
Evidence for the use of albendazole for the elimination of lymphatic filariasis.
Topics: Adolescent; Adult; Albendazole; Child; Clinical Trials as Topic; Diethylcarbamazine; Drug Therapy, C | 2006 |
Elimination of transmission of lymphatic filariasis in Egypt.
Topics: Albendazole; Animals; Culex; Diethylcarbamazine; Disease Vectors; Egypt; Elephantiasis, Filarial; Fi | 2006 |
Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Preschool; | 2006 |
Elimination of lymphatic filariasis.
Topics: Albendazole; Diethylcarbamazine; Egypt; Elephantiasis, Filarial; Filaricides; Humans; Models, Theore | 2006 |
Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Antiparasitic Agents; Bedding and | 2006 |
Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Communicat | 2006 |
Albendazole for mass drug administration to eliminate lymphatic filariasis.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; | 2006 |
Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India.
Topics: Adolescent; Adult; Albendazole; Animals; Antiparasitic Agents; Culex; Diethylcarbamazine; Elephantia | 2007 |
Impact of the 2004 mass drug administration for the control of lymphatic filariasis, in urban and rural areas of the Western province of Sri Lanka.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Anthelmintics; Child; Child, Presc | 2007 |
Endpoints for lymphatic filariasis programs.
Topics: Albendazole; Animals; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; Filari | 2007 |
National mass drug administration costs for lymphatic filariasis elimination.
Topics: Albendazole; Anthelmintics; Burkina Faso; Costs and Cost Analysis; Diethylcarbamazine; Dominican Rep | 2007 |
Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
Topics: Albendazole; Antinematodal Agents; Drug Monitoring; Drug Therapy, Combination; Elephantiasis, Filari | 2007 |
The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt.
Topics: Adolescent; Adult; Albendazole; Animals; Antigens, Helminth; Child; Cross-Sectional Studies; Diethyl | 2007 |
Triple drug administration (TDA), with praziquantel, ivermectin and albendazole, for the prevention of three neglected tropical diseases in Nigeria.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cost-Benefit Analysis; Drug Interactions; Drug The | 2008 |
At last, the fight against lymphatic filiariasis begins.
Topics: Albendazole; Anthelmintics; Elephantiasis, Filarial; Humans; International Cooperation; Ivermectin | 2000 |
Elimination of lymphatic filariasis as a public health problem.
Topics: Albendazole; Animals; Elephantiasis, Filarial; Filaricides; Humans; Ivermectin; Program Development; | 2000 |
Early-stage elephantiasis in bancroftian filariasis.
Topics: Adult; Albendazole; Animals; Developing Countries; Drug Therapy, Combination; Elephantiasis, Filaria | 2001 |
Filariasis elimination, Zanzibar.
Topics: Albendazole; Drug Therapy, Combination; Elephantiasis, Filarial; Female; Filaricides; Humans; Iverme | 2001 |
Lymphatic filariasis.
Topics: Albendazole; Anthelmintics; Developing Countries; Elephantiasis, Filarial; Endemic Diseases; Global | 2002 |
Mass drug administration to treat lymphatic filariasis.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Drug Therapy, Combination; Elephantiasis, Filarial; | 2002 |